

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number
WO 02/092128 A1

(51) International Patent Classification⁷: **A61K 39/395**,
38/00, A01N 43/04

(21) International Application Number: **PCT/US02/18609**

(22) International Filing Date: **13 May 2002 (13.05.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/290,483 11 May 2001 (11.05.2001) **US**
60/296,298 6 June 2001 (06.06.2001) **US**

(71) Applicant (for all designated States except US): **GEN-ZYME CORPORATION [US/US]**; One Kendall Square, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SCHIAVI, Susan, C. [US/US]**; 48 Wedgewood Drive, Hopkinton, MA 01748 (US). **FINNEGAN, Richard [US/US]**; 5 Merriam Way, Upton, MA 01568 (US).

(74) Agents: **KONSKI, Antoinette, F. et al.**; Bingham McCutchen LLP, Three Embarcadero Center, Suite 1800, San Francisco, CA 94111-4067 (US).

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.**

(84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/092128 A1

(54) Title: **COMPOSITIONS AND METHODS TO REGULATE SERUM PHOSPHATE**

(57) Abstract: The present invention relates to methods and compositions for regulating serum phosphate or phosphate homeostasis. More specifically, the present invention relates to methods and compositions for increasing or decreasing serum phosphate levels for the treatment and/or prevention of a variety of phosphate-related diseases by modulating the activity or expression of FRP 4, FGF 23 and PHEX. The methods of the invention are useful for increasing phosphate re-absorption or serum phosphate by delivering to a subject an agent that inhibits the activity of FGF 23 or FRP-4 or for decreasing phosphate re-absorption or serum phosphate by delivering to a subject an agent that enhances the activity FGF 23 or FRP-4 or inhibits the activity of PHEX. Also provided are methods for modulating renal phosphate transport, alleviating oncogenic osteomalacia-associated symptoms, treating phosphate homeostasis-related disease and modulating the phenotype of a neoplastic cell associated with OOM cell or a cell associated with phosphate homeostasis. In addition, the invention provides methods for detecting and monitoring expression of one or more of the FRP 4, FGF 23 and PHEX gene(s) or proteins. Finally, the invention provides methods for screening candidate agents to identify compositions that modify the activity or expression of FRP 4, FGF 23 and PHEX.

COMPOSITIONS AND METHODS TO REGULATE SERUM PHOSPHATE

RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. 119(e) of provisional
5 application serial number 60/296,298 filed June 6, 2001 and provisional application serial number
60/290,483 filed May 11, 2001 the disclosures of which are hereby incorporated by reference in
their entirety.

TECHNICAL FIELD

The present invention relates to methods and compositions for regulating serum
10 phosphate or phosphate homeostasis. More specifically, the present invention relates to
methods and compositions for increasing or decreasing serum phosphate levels for the
treatment and/or prevention of a variety of phosphate-related diseases and disorders in
subjects, such as warm-blooded animals including humans.

BACKGROUND OF THE INVENTION

15 Oncogenic osteomalacia (OOM) is an acquired hypophosphatemic syndrome
associated with a variety of mesenchymal tumors and is characterized by low serum levels of
phosphate and calcitriol, inappropriate phosphaturia secondary to inhibition of proximal renal
tubular phosphate reabsorption, and defective bone demineralization. Experimental evidence
suggests that OOM is caused by a humoral factor, termed phosphatonin (PTN), that is
20 produced by these mesenchymal tumors. Tumor extracts can inhibit phosphate transport *in*
vitro and produce phosphaturia and hypophosphatemia *in vivo*. Furthermore, surgical
removal of tumor tissue results in normalization of serum phosphorous and calcitriol,
reverses phosphaturia and eventually results in remineralization of bone.

The mesenchymal tumors that are associated with OOM are characteristically slow-
25 growing, complex, polymorphous neoplasms. Many of these mesenchymal tumors contain
areas of dystrophic calcification, osseous metaplasia, poorly differentiated foci of chondroid
tissue and osteoclast-like giant cells. The presence of these bony elements and calcification
suggest these tumors express genes that have important functions in bone formation and
mineralization.

30 OOM is clinically and biochemically similar to inherited disorders of phosphate
wasting, X-linked Hypophosphatemic Rickets (XLH) and Autosomal Dominant
Hypophosphatemic Rickets (ADHR). XLH is caused by haploinsufficiency of PHEX, an

endopeptidase whose substrate is yet undefined. Recently, missense mutations in FGF 23, a novel member of the fibroblast growth factor family, were identified in several kindreds with ADHR. Despite identification of the genes responsible for these inherited disorders of phosphate wasting, the mechanism by which haploinsufficiency of these genes results in renal phosphate wasting is unknown.

The PHEX gene (formerly PEX; Phosphate regulating gene with homologies to Endopeptidases on the X chromosome) was identified by a positional cloning approach as the candidate gene for X-linked hypophosphatemia (XLH), Francis et al. (1995) *Nat. Genetics* 11:130-136. Several groups have cloned and sequenced the human and mouse PHEX/phex cDNAs. Du et al. (1996) *Genomics* 36:22-28; Lipman et al. (1998) *J. Biol. Chem.* 273:13729-13737; Grieff et al. (1997) *Biochem. Biophys. Res. Comm.* 231:635-639; Beck et al. (1997) *J. Clin. Invest.* 99:1200-1209; Guo and Quarles (1997) *J. Bone Miner. Res.* 12:1009-1017; Strom et al. (1997) *Hum. Mol. Genet.* 6:165-171. Amino acid sequence comparisons have demonstrated homologies between PHEX protein and members of the neutral endopeptidase family as previously observed in the partial sequence of the candidate gene.

The mechanism by which loss of PHEX function elicits the bone and renal abnormalities observed in XLH patients is not clear. There are no data suggesting the presence of PHEX/phex mRNA in the kidney. Du et al. (1996) supra; Beck et al. (1997) supra; and Grieff et al. (1997) supra. The increased renal phosphate excretion in Hyp mice is due to a down-regulation of the phosphate transporter, which is necessary for the re-absorption of the phosphate from the nephron.

Therefore a need exists to identify and isolate phosphaturic humoral factors produced by the mesenchymal tumors and their relationship in dysregulation and disease progression. This invention satisfies this need and provides related advantages as well.

DESCRIPTION OF THE INVENTION

In one aspect, the present invention provides methods for modulating the phenotype of a neoplastic cell associated with oncogenic osteomalacia or a cell associated with phosphate homeostasis, comprising delivering an agent that alters the activity of FRP 4, FGF 23 or PHEX polypeptide within the cell.

In another aspect, the present invention provides methods for increasing phosphate re-absorption or increasing serum phosphate in a subject comprising delivering to the subject an effective amount of an agent that inhibits the activity of FRP 4 or FGF 23.

The invention also provides methods for decreasing phosphate re-absorption or
5 decreasing serum phosphate in a subject comprising delivering to the subject an effective amount of an agent that enhances the activity of FRP 4 or FGF 23 or inhibits the activity of PHEX. For example, a method of inhibiting the activity of FGF 23 and FRP 4 proteins in a subject may comprise delivering to the subject an effective amount of soluble PHEX protein, PHEX protein, a polynucleotide encoding soluble PHEX, a polynucleotide encoding PHEX, a
10 polynucleotide encoding anti-FGF 23 and/or anti-FRP 4 antibodies, or a composition comprising anti-FGF 23 and/or anti-FRP 4 antibodies.

In another aspect, the present invention provides a method of enhancing the biological activity of FGF 23 and/or FRP 4 proteins in a subject, comprising delivering to the subject an effective amount of an anti-PHEX antibody, a polynucleotide encoding an anti-PHEX
15 antibody, a polynucleotide encoding FGF 23 or FRP 4 proteins, or a composition comprising an effective amount of FGF 23 and/or FRP 4 proteins.

Other aspects of the invention include methods of enhancing the biological activity of FGF 23 and FRP 4 proteins in a subject comprising delivering to the subject an effective amount of an agent that inhibits transcription and/or translation of PHEX genes in the subject,
20 methods for modulating renal phosphate transport in a subject comprising delivering to the subject an effective amount of an agent that alters the activity of FRP 4 and FGF 23 or PHEX, in the subject, and methods of modulating renal phosphate transport comprising delivering to the subject an effective amount of an agent that alters the expression of FRP 4 and/or FGF 23 polynucleotides or PHEX polynucleotide.

25 This invention also provides methods for decreasing the biological activity of FRP 4 and FGF 23 proteins by delivering an effective amount of PHEX, or an agent that modulates PHEX gene expression and/or the biological activity of PHEX protein or stabilizes the PHEX protein. PHEX can be delivered as a polynucleotide encoding for PHEX or soluble PHEX protein. Soluble PHEX and/or PHEX proteins can also be utilized to regulate FRP 4 and
0 FGF 23.

This invention further provides methods for modulating phosphate homeostasis and/or renal phosphate transport by delivering agents that alter the expression or activity of PHEX, or stabilizes PHEX or the soluble PHEX protein which in turn alters the activity of FRP 4 and FGF 23 proteins. Pathologies, such as XLH and ADHR, that are caused by genetic

disregulation of these genes, are also ameliorated or treated. Other therapeutic benefits include, but are not limited to modulating bone mineralization, modulating renal phosphate transport, alleviating oncogenic osteomalacia-associated symptoms, treating phosphate homeostasis-related disease and FRP 4 related apoptosis and osteoarthritis (OA).

5 The invention further provides methods for increasing phosphate re-absorption or increasing serum phosphate by delivering to a subject one or more of PHEX protein, soluble PHEX protein, polynucleotides encoding PHEX and/or soluble PHEX, anti-FGF 23 and – FRP 4 antibodies and polynucleotides encoding anti-FGF 23 and –FRP 4 antibodies.

10 The invention further provides methods for increasing phosphate re-absorption or increasing serum phosphate by delivering to a subject PHEX and/or soluble PHEX and/or one or more agents that inhibit the stability (e.g., promote degradation or inactivation) of the FGF 23 and FRP 4 proteins.

15 This invention provides isolated polynucleotides useful in the methods identified herein. The polynucleotides encode FRP 4 protein, PHEX, and FGF 23, ADHR mutant, FGF 23, (hereinafter “mutant FGF 23”) as well as antibodies that specifically recognize and bind these proteins, and are intended to include DNA, cDNA, RNA and genomic DNA. Expression systems, including gene delivery vehicles such as liposomes and vectors, and host cells containing the polynucleotides are further provided by this invention.

20 The present invention also provides proteins encoded by the polynucleotides. Additionally, nucleic acid probes and primers that hybridize to invention polynucleotides are provided, as well as isolated nucleic acids comprising unique, expressed gene sequences.

25 The present invention further includes antisense oligonucleotides (e.g., antisense FGF-23 or antisense FRP-4), antibodies (e.g., anti FGF-23 or anti FRP-4), hybridoma cell lines and compositions containing same.

 The present invention also provides methods of monitoring gene expression using invention polynucleotides.

30 The methods of monitoring gene expression are useful for detecting a cell expressing oncogenic osteomalacia-related polypeptide and for detecting a neoplastic cell associated with oncogenic osteomalacia.

 This invention further provides methods for modulating the expression of the inventive polynucleotides, for altering the activity of the proteins encoded by the polynucleotides, and for treating symptoms of phosphate transport related diseases and diseases characterized by abnormal bone mineralization. These diseases include but are not

limited to, oncogenic osteomalacia, X-linked hypophosphataemia rickets, rhabdomyolysis, osteoporosis, cardiomyopathy, tumoral calcinosis, osteoarthritis, renal failure and bone mineralization.

This invention also provides a method for screening for candidate agents that
5 modulate the expression of a polynucleotide or its complement, or modulate the level, activity or stability of the polypeptide of the invention, by contacting a test agent with a neoplastic cell associated with oncogenic osteomalacia or a cell associated with phosphate homeostasis and monitoring expression of the polynucleotide, wherein the test agent which
10 modifies the expression of the polynucleotide or modifies the level, activity or stability of the polypeptide is a candidate agent.

This invention also provides a method for screening for candidate agents that inhibit
the protein stability (e.g., enhances degradation) of the FGF-23 or FRP-4 protein, by
contacting a test agent with a neoplastic cell associated with oncogenic osteomalacia or a cell
associated with phosphate homeostasis and monitoring expression of the polynucleotide,
15 wherein the test agent which results in an inhibition of stability (e.g., promote degradation or inactivation) of the FGF-23 or FRP-4 protein is a candidate agent.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

- Sequence ID NO. 1 is a polynucleotide encoding FRP 4. Genbank Accession No. NM 003014.
- 20 Sequence ID NO. 2 is an amino acid sequence of an FRP 4 protein.
- Sequence ID NO. 3 is a polynucleotide encoding FGF 23. See also Genbank Accession No. AB047858.
- Sequence ID NO. 4 is an amino acid sequence of an FGF 23 protein. See also Genbank Accession No. AB047858.
- 25 Sequence ID NO. 5 is a polynucleotide encoding PHEX. See also Francis, et al. (1995) supra.
- Sequence ID NO. 6 is an amino acid sequence of a PHEX protein. See also Francis et al. (1995), supra.
- Sequence ID NO. 7 is a primer for GNAS1.
- Sequence ID NO. 8 is a second primer for GNAS1.
- Sequence ID NO. 9 is a primer for MEPE.
- Sequence ID NO. 10 is a second primer for MEPE.

Sequence ID NO. 11 is a primer for FRP 4.

Sequence ID NO. 12 is a second primer for FRP 4.

Sequence ID NO. 13 is a primer for PHEX.

Sequence ID NO. 14 is a second primer for PHEX.

- 5 The amino acid sequence for soluble PHEX polypeptide is published as Figure 2 of WO 00/50580. Polynucleotide sequence encoding the polypeptide are available by reverse translation of the peptide. Computer software is available on the web to reverse translate proteins. See <http://arbl.cvmb.colostate.edu/molkit/rtranslate>.

MODE(S) FOR CARRYING OUT THE INVENTION

- 10 Throughout this disclosure, various publications, patents and published patent specifications are referenced by an identifying citation. The disclosures of these publications, patents and published patent specifications are hereby incorporated by reference into the present disclosure to more fully describe the state of the art to which this invention pertains.

Definitions

- 15 The practice of the present invention will employ, unless otherwise indicated, conventional techniques of immunology, molecular biology, microbiology, cell biology and recombinant DNA. These methods are described in the following publications. See, e.g., Sambrook, et al. MOLECULAR CLONING: A LABORATORY MANUAL, 2nd edition (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel, et al. eds., (1987)); the
20 series METHODS IN ENZYMOLOGY (Academic Press, Inc.); "PCR: A PRACTICAL APPROACH" (M. MacPherson, et al., IRL Press at Oxford University Press (1991)); PCR 2: A PRACTICAL APPROACH (M.J. MacPherson, B.D. Hames and G.R. Taylor eds. (1995)); ANTIBODIES, A LABORATORY MANUAL (Harlow and Lane, eds. (1988)); and ANIMAL CELL CULTURE (R.I. Freshney, ed. (1987)).

- 25 As used in the specification and claims, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a cell" includes a plurality of cells, including mixtures thereof.

- 30 The term "comprising" is intended to mean that the compositions and methods include the recited elements, but not excluding others. "Consisting essentially of" when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements

as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. "Consisting of" shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition terms are within the scope of this invention.

The terms "polynucleotide" and "nucleic acid molecule" are used interchangeably to refer to polymeric forms of nucleotides of any length. The polynucleotides may contain deoxyribonucleotides, ribonucleotides, and/or their analogs. Nucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The term "polynucleotide" includes, for example, single-, double-stranded and triple helical molecules, a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A nucleic acid molecule may also comprise modified nucleic acid molecules.

A "gene" refers to a polynucleotide containing at least one open reading frame that is capable of encoding a particular polypeptide or protein after being transcribed and translated.

An "FRP 4 gene" is a polynucleotide comprising an ordered sequence of nucleotides located in a particular position on a particular chromosome that encodes a polypeptide, such as the amino acid sequence shown in SEQ ID NO 2. The term gene is intended to include contiguous polynucleotide sequences such as promoters and enhancers that modulate expression. As used herein the term FRP 4 gene refers to all orthologous sequences from divergent species, ie. homologous sequences encoding polypeptides that have the same activity in different species. It is particularly intended to include the FRP 4 genes of humans, simians and rodents.

An "FRP 4 polynucleotide" means any ordered sequence of polynucleotides that encode polypeptide, a portion of such a peptide, or a portion of the FRP 4 gene. An "FRP 4 polynucleotide" thus include cDNA's, probes, primers, and other molecules comprising polynucleotide sequences derived from the complete FRP 4 gene, eg. biologically equivalent polynucleotides.

An "FGF 23 gene" is a polynucleotide comprising an ordered sequence of nucleotides located in a particular position on a particular chromosome that encodes a polypeptide, such as the amino acid sequence shown in SEQ ID NO 4. The term gene is intended to include contiguous polynucleotide sequences such as promoters and enhancers that modulate

expression. As used herein the term FGF 23 gene refers to all orthologous sequences from divergent species, ie. homologous sequences encoding polypeptides that have the same activity in different species. It is particularly intended to include the FGF 23 genes of humans, simians and rodents.

5 An "FGF 23 polynucleotide" means any ordered sequence of polynucleotides that encode polypeptide, a portion of such a peptide, or a portion of the FGF 23 gene. An "FGF 23 polynucleotide" thus include cDNA's, probes, primers, and other molecules comprising polynucleotide sequences derived from the complete FGF 23 gene, eg. biologically equivalent polynucleotides.

10 A "mutant FGF 23 polynucleotide" means any ordered sequence of polynucleotides that encode polypeptide, a portion of a peptide, or a portion of a mutant FGF 23 polypeptide that retains the ability to inhibit phosphate uptake in renal epithelial cells, but is not cleaved by PHEX. Examples include, but are not limited to R179Q (amino acid 179 is mutated to Q); R179W (amino acid 179 is mutated to W) and R176Q (amino acid 176 is mutated to Q).

15 These are described in Nature (2000) 26:345-348 and can be obtained by modification of wild-type FGF 23 shown in SEQ ID NO 3(polynucleotide) and SEQ ID NO 4 (polypeptide).

A "PHEX gene" is a polynucleotide comprising an ordered sequence of nucleotides located in a particular position on a particular chromosome that encodes a polypeptide, such as the amino acid sequence shown in SEQ ID NO 6. The term gene is intended to include
20 contiguous polynucleotide sequences such as promoters and enhancers that modulate expression. As used herein the term PHEX gene refers to all orthologous sequences from divergent species, ie. homologous sequences encoding polypeptides that have the same activity in different species. It is particularly intended to include the PHEX genes of humans, simians and rodents.

25 An "PHEX polynucleotide" means any ordered sequence of polynucleotides that encode polypeptide, a portion of such a peptide, eg., soluble PHEX or a portion of the PHEX gene. An "PHEX polynucleotide" thus include cDNA's, probes, primers, and other molecules comprising polynucleotide sequences derived from the complete PHEX gene, eg. biologically equivalent polynucleotides.

30 Biologically equivalent polynucleotides are polynucleotides which differ from the polynucleotides described above, but produce the same phenotypic effect, such as the allele, splice variant and homolog. These altered, but phenotypically equivalent polynucleotides are referred to as "biologically equivalent polynucleotide" and "equivalent nucleic acids." The methods of the invention also encompasses polynucleotides characterized by changes in non-

coding regions that do not alter the phenotype of the polypeptide produced therefrom when compared to the polynucleotide herein. This invention further envisions the use of polynucleotides, which hybridize to the polynucleotides of the subject invention under conditions of moderate or high stringency.

5 Biologically equivalent polynucleotides useful in the methods of this invention are identified using sequence homology searches. Several embodiments of biologically equivalent polynucleotides are within the scope of this invention, e.g., those characterized by possessing at least 75%, or at least 80%, or at least 90% or at least 95% sequence homology as determined using a sequence alignment program under default parameters correcting for
10 ambiguities in the sequence data, changes in nucleotide sequence that do not alter the amino acid sequence because of degeneracy of the genetic code, conservative amino acid substitutions and corresponding changes in nucleotide sequence, and variations in the lengths of the aligned sequences due to splicing variants or small deletions or insertions between sequences that do not affect function.

15 A variety of software programs are available in the art. Non-limiting examples of these programs are BLAST family programs including BLASTN, BLASTP, BLASTX, TBLASTN, and TBLASTX (BLAST is available from the worldwide web at <http://www.ncbi.nlm.nih.gov/BLAST/>), FastA, Compare, DotPlot, BestFit, GAP, FrameAlign, ClustalW, and PileUp. These programs can be obtained commercially in a
20 comprehensive package of sequence analysis software such as GCG Inc.'s Wisconsin Package. Other similar analysis and alignment programs can be purchased from various providers such as DNA Star's MegAlign, or the alignment programs in GeneJockey. Alternatively, sequence analysis and alignment programs can be accessed through the world wide web at sites such as the CMS Molecular Biology Resource at
25 <http://www.sdsc.edu/ResTools/cmshp.html>. Any sequence database that contains DNA or protein sequences corresponding to a gene or a segment thereof can be used for sequence analysis. Commonly employed databases include but are not limited to GenBank, EMBL, DDBJ, PDB, SWISS-PROT, EST, STS, GSS, and HTGS. Sequence similarity can be discerned by aligning the tag sequence against a DNA sequence database. Alternatively, the tag sequence can be translated into six reading frames; the predicted peptide sequences of all possible reading frames are then compared to individual sequences stored in a protein database such as s done using the BLASTX program.

Parameters for determining the extent of homology set forth by one or more of the mentioned alignment programs are well established in the art. They include but are not

limited to p value, percent sequence identity and the percent sequence similarity. P value is the probability that the alignment is produced by chance. For a single alignment, the p value can be calculated according to Karlin et al. (1990) PNAS 87: 2246. For multiple alignments, the p value can be calculated using a heuristic approach such as the one programmed in

5 BLAST. Percent sequence identify is defined by the ratio of the number of nucleotide or amino acid matches between the query sequence and the known sequence when the two are optimally aligned. The percent sequence similarity is calculated in the same way as percent identity except one scores amino acids that are different but similar as positive when calculating the percent similarity. Thus, conservative changes that occur frequently without

10 altering function, such as a change from one basic amino acid to another or a change from one hydrophobic amino acid to another are scored as if they were identical. A tag sequence is considered to lack substantial homology with any known sequences when the regions of alignment of comparable length exhibit less than 30% of sequence identity, more preferably less than 20% identity, even more preferably less than 10% identity.

15 Based on the known sequence of the FRP 4, FGF 23, mutant FGF 23, or PHEX gene, fragments of the gene or the full length coding sequence of the corresponding transcript or gene can be identified using various cloning methods known to artisans in the art. Polynucleotides useful for practicing the methods of the invention can comprise additional sequences, such as additional coding sequences within the same transcription unit, controlling

20 elements such as promoters, ribosome binding sites, and polyadenylation sites, additional transcription units under control of the same or a different promoter, sequences that permit cloning, expression, and transformation of a host cell, and any such construct as may be desirable to provide embodiments of this invention.

A "FRP 4 polypeptide" is a molecule comprising an ordered sequence of amino acids

25 specified by translation of a FRP 4 cDNA, such as is shown in SEQ ID NO 2. The term is used to refer to the complete FRP 4 amino acid sequence of FRP 4 (SEQ ID NO 2) as well as to alternatively spliced polypeptide molecules, and other portions of the complete molecule, such as protease cleavage products and synthetic peptides derived from the complete sequence. It also refers to orthologous FRP 4 polypeptides derived from various species

30 including, but not limited to humans, simians, and rodents.

A "FGF 23 polypeptide" is a molecule comprising an ordered sequence of amino acids specified by translation of a FGF 23 cDNA, such as is shown in SEQ ID NO 4. The term is used to refer to the complete FGF 23 amino acid sequence of FGF 23 (SEQ ID NO 4) as well as to alternatively spliced polypeptide molecules, and other portions of the complete

molecule, such as protease cleavage products and synthetic peptides derived from the complete sequence. It also refers to orthologous FGF 23 polypeptides derived from various species including, but not limited to humans, simians, and rodents.

5 "Mutant FGF 23" is a mutated form of FGF 23 polypeptide that retains the ability to inhibit phosphate uptake in renal epithelial cells, but is not a substrate for PHEX. A "mutant FGF 23 polynucleotide" means any ordered sequence of polynucleotides that encode polypeptide, a portion of a peptide, or a portion of a mutant FGF 23 polypeptide that retains the ability to inhibit phosphate uptake in renal epithelial cells, but is not cleaved by PHEX. Examples include, but are not limited to R179Q (amino acid 179 is mutated to Q); R179W
10 (amino acid 179 is mutated to W) and R176Q (amino acid 176 is mutated to Q). These are described in Nature (2000) 26:345-348 and can be obtained by modification of wild-type FGF 23 shown in SEQ ID NO 3(polynucleotide) and SEQ ID NO 4 (polypeptide).

A "PHEX polypeptide" is a molecule comprising an ordered sequence of amino acids specified by translation of a PHEX cDNA, such as is shown in SEQ ID NO 6. The term is
15 used to refer to the complete amino acid sequence of PHEX, soluble PHEX, (SEQ ID NO 6) as well as to alternatively spliced polypeptide molecules, and other portions of the complete molecule, such as protease cleavage products and synthetic peptides derived from the complete sequence. It also refers to orthologous PHEX polypeptides derived from various species including, but not limited to humans, simians, and rodents.

20 A "gene product" refers to the amino acid (e.g., peptide or polypeptide) generated when a gene is transcribed and translated.

A "sequence tag" or "tag" or "SAGE tag" is a short oligonucleotide containing defined nucleotide sequence that occurs in a certain position of a gene transcript. The length of a tag is generally under about 20 nucleotides, preferably between 9 to 15 nucleotides, and
25 more preferably 10 nucleotides. The tag can be used to identify the corresponding transcript and gene from which it was transcribed. A tag can further comprise exogenous nucleotide sequences to facilitate the identification and utility of the tag. Such auxiliary sequences include, but are not limited to, restriction endonuclease cleavage sites and well known primer sequences for sequencing and cloning.

A sequence is the complement or is complementary to another sequence if they are related by the base-pairing rules. For example, in DNA, a sequence A-G-T in one strand is complementary to T-C-A in the other strand. A given sequence defines the complementary
sequence.

As used herein, the term "modulate" means to alter or modify an identified process or biological function, e.g., phosphate transport, phosphate reabsorption, FRP 4-regulated apoptosis and osteoarthritis.

The term "peptide" is used in its broadest sense to refer to a compound of two or more subunit amino acids, amino acid analogs, or peptidomimetics. The subunits may be linked by peptide bonds. In another embodiment, the subunit may be linked by other bonds, e.g. ester, ether, etc. As used herein the term "amino acid" refers to either natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics. A peptide of three or more amino acids is commonly called an oligopeptide if the peptide chain is short. If the peptide chain is long, the peptide is commonly called a polypeptide or a protein.

The term "cDNAs" refers to complementary DNA, that is mRNA molecules present in a cell or organism made in to cDNA with an enzyme such as reverse transcriptase. A "cDNA library" is a collection of all of the mRNA molecules present in a cell or organism, all turned into cDNA molecules with the enzyme reverse transcriptase, then inserted into "vectors".

A "probe" when used in the context of polynucleotide manipulation refers to an oligonucleotide that is provided as a reagent to detect a target potentially present in a sample of interest by hybridizing with the target. Usually, a probe will comprise a label or a means by which a label can be attached, either before or subsequent to the hybridization reaction. Suitable labels include, but are not limited to radioisotopes, fluorochromes, chemiluminescent compounds, dyes, and proteins, including enzymes.

A "primer" is a short polynucleotide, generally with a free 3' -OH group that binds to a target or "template" potentially present in a sample of interest by hybridizing with the target, and thereafter promoting polymerization of a polynucleotide complementary to the target. A "polymerase chain reaction" ("PCR") is a reaction in which replicate copies are made of a target polynucleotide using a "pair of primers" or a "set of primers" consisting of an "upstream" and a "downstream" primer, and a catalyst of polymerization, such as a DNA polymerase, and typically a thermally-stable polymerase enzyme. Methods for PCR are well known in the art, and taught, for example in "PCR: A PRACTICAL APPROACH" (M. MacPherson *et al.*, IRL Press at Oxford University Press (1991)). All processes of producing replicate copies of a polynucleotide, such as PCR or gene cloning, are collectively referred to herein as "replication." A primer can also be used as a probe in hybridization reactions, such as Southern or Northern blot analyses. Sambrook et al., *supra*.

A "promoter" is a region on a DNA molecule to which an RNA polymerase binds and initiates transcription. In an operon, the promoter is usually located at the operator end, adjacent but external to the operator. The nucleotide sequence of the promoter determines both the nature of the enzyme that attaches to it and the rate of RNA synthesis.

5 The term "genetically modified" means containing and/or expressing a foreign gene or nucleic acid sequence which in turn, modifies the genotype or phenotype of the cell or its progeny. "Foreign nucleic acid" includes, but is not limited to promoters, enhancers and gene activators. For example, a genetically modified cell includes a cell that contains a polynucleotide encoding PHEX polypeptide in its native environment but not expressed and
10 expression has been turned on or the level of expression has been enhanced or lowered by the upstream insertion of a gene activator.

As used herein, "expression" or "expressed" refers to the process by which polynucleotides are transcribed into mRNA or by which transcription is enhanced. In another embodiment, the RNA is translated into peptides, polypeptides, or proteins. If the
15 polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA, if an appropriate eukaryotic host is selected.

"Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding may occur by Watson-Crick base pairing, Hoogsteen
20 binding, or in any other sequence-specific manner. The complex may comprise two strands forming a duplex structure, three or more strands forming a multi-stranded complex, a single self-hybridizing strand, or any combination of these. A hybridization reaction may constitute a step in a more extensive process, such as the initiation of a PCR reaction, or the enzymatic cleavage of a polynucleotide by a ribozyme.

25 Hybridization reactions can be performed using traditional hybridization techniques under different stringency. In general, a low stringency hybridization reaction is carried out at about 40°C in 10 X SSC or a solution of equivalent ionic strength/temperature. A moderate stringency hybridization is typically performed at about 50°C in 6 X SSC, and a high stringency hybridization reaction is generally performed at about 60°C in 1 X SSC.
30 Alternatively, TMAC hybridization technology can be used for hybridization reactions probed with pooled oligonucleotides such as the SAGE tags. The advantage of using TMAC hybridization is that the reaction condition is not dependent on the G+C content of the oligonucleotide, and the melting temperature is determined only by the length of the oligomers to be used.

When hybridization occurs in an anti-parallel configuration between two single-stranded polynucleotides, the reaction is called "annealing" and those polynucleotides are described as "complementary". A double-stranded polynucleotide can be "complementary" or "homologous" to another polynucleotide, if hybridization can occur between one of the strands of the first polynucleotide and the second. "Complementarity" or "homology" (the degree that one polynucleotide is complementary with another) is quantifiable in terms of the proportion of bases in opposing strands that are expected to form hydrogen bonding with each other, according to generally accepted base-pairing rules. A polynucleotide that is 100% complementary to a second polynucleotide are understood to be "complements" of each other.

A "composition" is intended to mean a combination of active agent and another compound or composition, inert (for example, a detectable agent or label or a pharmaceutically acceptable carrier) or active, such as an adjuvant.

A "pharmaceutical composition" is intended to include the combination of an active agent with a carrier, inert or active, making the composition suitable for diagnostic or therapeutic use *in vitro*, *in vivo* or *ex vivo*.

As used herein, the term "pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see Martin, REMINGTON'S PHARM. SCI., 15th Ed. (Mack Publ. Co., Easton (1975)).

An "effective amount" is an amount sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages. Examples of beneficial or desired results include, but are not limited to an increase in phosphate reabsorption or an increase in serum phosphate.

A "subject," "individual" or "patient" is used interchangeably herein, which refers to a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets.

A "control" is an alternative subject or sample used in an experiment for comparison purpose. A control can be "positive" or "negative". For example, where the purpose of the experiment is to determine a correlation of an altered expression level of a gene with a particular type of cancer, it is generally preferable to use a positive control (a subject or a sample from a subject, carrying such alteration and exhibiting syndromes characteristic of

that disease), and a negative control (a subject or a sample from a subject lacking the altered expression and clinical syndrome of that disease).

A "gene delivery vehicle" is defined as any molecule that can carry inserted polynucleotides into a host cell. Examples of gene delivery vehicles are liposomes, cationic liposomes, viruses, such as baculovirus, adenovirus, adeno-associated virus, and retrovirus, bacteriophage, cosmid, plasmid, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression.

A "viral vector" is defined as a recombinantly produced virus or viral particle that comprises a polynucleotide to be delivered into a host cell, either *in vivo*, *ex vivo* or *in vitro*. Examples of viral vectors include retroviral vectors, adenovirus vectors, adeno-associated virus vectors and the like. In aspects where gene transfer is mediated by a retroviral vector, a vector construct refers to the polynucleotide comprising the retroviral genome or part thereof, and the inserted polynucleotide. As used herein, "retroviral mediated gene transfer" or "retroviral transduction" carries the same meaning and refers to the process by which a gene or nucleic acid sequences are stably transferred into the host cell by virtue of the virus entering the cell and integrating its genome into the host cell genome. The virus can enter the host cell via its normal mechanism of infection or be modified such that it binds to a different host cell surface receptor or ligand to enter the cell. As used herein, retroviral vector refers to a viral particle capable of introducing exogenous nucleic acid into a cell through a viral or viral-like entry mechanism.

Retroviruses carry their genetic information in the form of RNA; however, once the virus infects a cell, the RNA is reverse-transcribed into the DNA form that integrates into the genomic DNA of the infected cell. The integrated DNA form is called a provirus.

In aspects where gene transfer is mediated by a DNA viral vector, such as an adenovirus (Ad) or adeno-associated virus (AAV), a vector construct refers to the polynucleotide comprising the viral genome or part thereof, and a polynucleotide to be inserted. Adenoviruses (Ads) are a relatively well characterized, homogenous group of viruses, including over 50 serotypes. (see, *e.g.*, WO 95/27071). Ads are easy to grow and do not require integration into the host cell genome. Recombinant Ad-derived vectors, particularly those that reduce the potential for recombination and generation of wild-type virus, have also been constructed. (see, WO 95/00655; WO 95/11984). Wild-type AAV has high infectivity and specificity integrating into the host cells genome. (Hermonat and

Muzyczka (1984) PNAS USA 81:6466-6470; Lebkowski, et al. (1988) Mol. Cell. Biol. 8:3988-3996).

Vectors that contain both a promoter and a cloning site into which a polynucleotide can be operatively linked are well known in the art. Such vectors are capable of transcribing
5 RNA *in vitro* or *in vivo*, and are commercially available from sources such as Stratagene (La Jolla, CA) and Promega Biotech (Madison, WI). In order to optimize expression and/or *in vitro* transcription, it may be necessary to remove, add or alter 5' and/or 3' untranslated portions of the clones to eliminate extra, potential inappropriate alternative translation initiation codons or other sequences that may interfere with or reduce expression, either at the
10 level of transcription or translation. Alternatively, consensus ribosome binding sites can be inserted immediately 5' of the start codon to enhance expression.

Gene delivery vehicles also include several non-viral vectors, including DNA/liposome complexes, and targeted viral protein DNA complexes. Liposomes that also comprise a targeting antibody or fragment thereof can be used in the methods of this
15 invention. To enhance delivery to a cell, the nucleic acid or proteins of this invention can be conjugated to antibodies or binding fragments thereof which bind cell surface antigens, e.g., TCR, CD3 or CD4.

Polynucleotides are inserted into vector genomes using methods well known in the art. For example, insert and vector DNA can be contacted, under suitable conditions, with a
20 restriction enzyme to create complementary ends on each molecule that can pair with each other and be joined together with a ligase. Alternatively, synthetic nucleic acid linkers can be ligated to the termini of restricted polynucleotide. These synthetic linkers contain nucleic acid sequences that correspond to a particular restriction site in the vector DNA. Additionally, an oligonucleotide containing a termination codon and an appropriate
25 restriction site can be ligated for insertion into a vector containing, for example, some or all of the following: a selectable marker gene, such as the neomycin gene for selection of stable or transient transfectants in mammalian cells; enhancer/promoter sequences from the immediate early gene of human CMV for high levels of transcription; transcription termination and RNA processing signals from SV40 for mRNA stability; SV40 polyoma
30 origins of replication and ColE1 for proper episomal replication; versatile multiple cloning sites; stabilizing elements 3' to the inserted polynucleotide, and T7 and SP6 RNA promoters for *in vitro* transcription of sense and antisense RNA. Other means are well known and available in the art.

“Host cell” is intended to include any individual cell or cell culture that can be or have been recipients for vectors or the incorporation of exogenous polynucleotides, polypeptides and/or proteins. It also is intended to include progeny of a single cell, and the progeny may not necessarily be completely identical (in morphology or in genomic or total DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. The cells may be prokaryotic or eukaryotic, and include but are not limited to bacterial cells, yeast cells, plant cells, insect cells, animal cells, and mammalian cells, e.g., murine, rat, simian or human.

An “antibody” is an immunoglobulin molecule capable of binding an antigen. As used herein, the term encompasses not only intact immunoglobulin molecules, but also anti-idiotypic antibodies, mutants, fragments, fusion proteins, humanized proteins and modifications of the immunoglobulin molecule that comprise an antigen recognition site of the required specificity.

As used herein, “expression” refers to the process by which polynucleotides are transcribed into mRNA and translated into peptides, polypeptides, or proteins. If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA, if an appropriate eukaryotic host is selected. Regulatory elements required for expression include promoter sequences to bind RNA polymerase and transcription initiation sequences for ribosome binding. For example, a bacterial expression vector includes a promoter such as the *lac* promoter and for transcription initiation the Shine-Dalgarno sequence and the start codon AUG (Sambrook, et al. (1989) *supra*). Similarly, an eukaryotic expression vector includes a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome. Such vectors can be obtained commercially or assembled by the sequences described in methods well known in the art, for example, the methods described below for constructing vectors in general.

A “subject” is a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets.

A “control” is an alternative subject or sample used in an experiment for comparison purpose. A control can be “positive” or “negative.”

The term “culturing” refers to the *in vitro* propagation of cells or organisms on or in media of various kinds. It is understood that the descendants of a cell grown in culture may

not be completely identical (i.e., morphologically, genetically, or phenotypically) to the parent cell. By "expanded" is meant any proliferation or division of cells.

The terms "cancer," "neoplasm," and "tumor," used interchangeably and in either the singular or plural form, refer to cells that have undergone a malignant transformation that makes them pathological to the host organism. Primary cancer cells (that is, cells obtained from near the site of malignant transformation) can be readily distinguished from non-cancerous cells by well-established techniques, particularly histological examination. The definition of a cancer cell, as used herein, includes not only a primary cancer cell, but any cell derived from a cancer cell ancestor. This includes metastasized cancer cells, and *in vitro* cultures and cell lines derived from cancer cells. When referring to a type of cancer that normally manifests as a solid tumor, a "clinically detectable" tumor is one that is detectable on the basis of tumor mass; e.g., by such procedures as CAT scan, magnetic resonance imaging (MRI), X-ray, ultrasound or palpation. Biochemical or immunologic findings alone may be insufficient to meet this definition. Tumor cells often express antigens which are tumor specific. The term "tumor associated antigen" or "TAA" refers to an antigen that is associated with or specific to a tumor.

As used herein, "solid phase support" is not limited to a specific type of support. Rather a large number of supports are available and are known to one of ordinary skill in the art. Solid phase supports include silica gels, resins, derivatized plastic films, glass beads, cotton, plastic beads, alumina gels. A suitable solid phase support may be selected on the basis of desired end use and suitability for various synthetic protocols. For example, for peptide synthesis, solid phase support may refer to resins such as polystyrene (e.g., PAM-resin obtained from Bachem Inc., Peninsula Laboratories, etc.), POLYHIPE[®] resin (obtained from Aminotech, Canada), polyamide resin (obtained from Peninsula Laboratories), polystyrene resin grafted with polyethylene glycol (TentaGel[™], Rapp Polymere, Tubingen, Germany) or polydimethylacrylamide resin (obtained from Milligen/Bioscience, California). In a preferred embodiment for peptide synthesis, solid phase support refers to polydimethylacrylamide resin.

A "transgenic animal" refers to a genetically engineered animal or offspring of genetically engineered animals. The transgenic animal may contain genetic material from at least one unrelated organism (such as from a bacteria, virus, plant, or other animal) or may contain a mutation which interferes with expression of a gene product.

The term "oncogenic osteomalacia" (OOM), "oncogenic hypophosphatemic osteomalacia" (OHO), or "tumor-associated osteomalacia" refers to a tumor-acquired syndrome characterized mainly by hypophosphatemia, hyperphosphaturia, abnormally low serum level of 1,25-dihydroxyvitamin D, and osteomalacia. Tumors associated with OOM are mainly of mesenchymal origin such as hemangiopericytomas, although carcinoma of prostate and lung, fibrous dysplasia of bone, linear sebaceous naevus syndrome, neurofibromatosis, and oat cell carcinoma are also associated with OOM. Thus, the OOM syndrome can be described as having a paraneoplastic etiology. Surgical removal of the tumor in a patient often results in a complete or near-complete resolution of biochemical and clinical defects associated with OOM.

Oncogenic osteomalacia-related genes include genes that have been identified to be over-expressed or under-expressed relative to control tumors (histologically similar tumors that are not associated with OOM). Genes that are up-regulated or down-regulated in oncogenic osteomalacia may encode proteins involved in several distinct biochemical pathways. These include phosphate regulation, bone mineralization, and protein synthesis, processing and secretion.

The regulation of phosphate metabolism plays a central role in mediating the symptoms of oncogenic osteomalacia. Genes whose expression is altered in OOM tumors can affect phosphate metabolism through a variety of mechanisms. For example, the tumor may directly produce increased amounts of phosphatonin, a secreted humoral factor whose activity includes inhibition of phosphate re-absorption in the kidney. Alternatively the OOM tumor cells could produce a factor or factors that alter the expression in the kidney of accessory polypeptides required for mediating the effects of phosphatonin such as the phosphatonin receptor and intracellular proteins responsible for eliciting the effects of phosphatonin. FRP 4, FGF 23, both of which exhibit phosphatonin activity, and PHEX are genes involved in the regulation of the phosphatonin pathway.

Altered gene expression by OOM tumor cells can also alter phosphate metabolism by more complex mechanisms. For example tumor produced factors could up-regulate expression of genes normally controlled directly by phosphatonin or in response to phosphatonin. Such OOM tumor produced factors could increase expression of phosphate transport molecules and other cellular proteins necessary for regulating either phosphate uptake or secretion of phosphate. Alternatively, OOM tumor factors could alter expression of extracellular regulators or carriers of phosphate or phosphatonin.

OOM-related genes that modulate phosphate metabolism are useful candidates for developing therapeutic agents for a variety of disease conditions related to abnormal phosphate metabolism. These include renal conditions such as renal osteodystrophy, changes in phosphate homeostasis after kidney transplant, end stage renal disease (ESRD), and acute renal disease, bone defects, hypophosphataemia, hyperphosphataemia, hypoparathyroidism, and pseudohypoparathyroidism.

Phosphate metabolism related factors could provide useful mediators of disease conditions through a variety of alternative mechanisms. For example, during ESRD, phosphatonin or other proteins in its pathway may inhibit absorption of phosphate in the small intestine. Such factors may also enhance phosphate uptake in the proximal tubules of the kidney. Modulation of the activity of these factors could therefore be used to control the symptoms of this disease.

In conditions characterized by hypophosphatemia or low serum phosphate levels, blocking FGF 23 and FRP 4 or enhancing production or the local concentration of PHEX is an effective therapy because enhanced FGF 23 and FRP 4 protein levels have been linked to hypophosphatemia. In addition, FGF 23 and FRP 4 are substrates for PHEX; PHEX inactivates these proteins. Mutant FGF 23 inhibits phosphate uptake in renal epithelial cells but it is not cleaved by PHEX. This type of therapy is useful for a range of conditions including hyperparathyroidism, X-linked hypophosphatemic rickets, vitamin D dependent rickets, Franconi Syndrome, post kidney transplant condition, and oncogenic osteomalacia.

Serum phosphate levels can be increased, or alternatively, phosphate re-absorption can be increased by inhibiting FRP 4 and FGF 23 or by delivering or enhancing PHEX expression, or by delivering agents that produce this effect in the subject. By way of example, FGF 23 and FRP-4 can be inhibited by administering an agent that inhibits, decreases or represses the protein stability (e.g., promotes degradation or inactivation) of FGF 23 and FRP-4. Examples of such agents include, but are not limited to, proteases, such as PHEX or soluble PHEX.

Diseases characterized by increased phosphate levels or hyperphosphatemia could be affected by treatment directed towards any protein that acts in the phosphatonin pathway to lower serum phosphate levels or to reduce phosphate re-absorption. Diseases related to hyperphosphatemia include: hypoparathyroidism (levels of PTH secreted are insufficient to maintain extracellular calcium and phosphate levels-leads to hypocalcemia and hyperphosphatemia); pseudohypoparathyroidism (a group of disorders characterized by biochemical hypoparathyroidism, hypocalcemia and hyperphosphatemia, increased secretion

of PTH and resistance to the biological actions of PTH); transcellular phosphate shift from cells into the extracellular fluid caused by systemic infections, severe hyperthermia, crush injuries, non-traumatic rhabdomyolysis, and tumor lysis syndrome after cytotoxic therapies for hematologic malignancies; and renal disease. Serum phosphate levels can be decreased, or alternatively, phosphate re-absorption can be decreased by enhancing FRP 4 and FGF 23 activity or protein stability (e.g., inhibit degradation, such as by using a mutant FGF 23 resistant to degradation) or by inhibiting PHEX expression, or activity.

In addition to modulation of phosphate metabolism, factors whose expression is altered in OOM tumor cells can include genes whose polypeptide products act directly on osteogenic cells to mediate bone mineralization. Such proteins associated with OOM may either promote or inhibit diseases associated with defective mineralization. Possible functions of proteins in the bone mineralization pathway include: inhibition of bone mineralization, regulation of the early stages of bone mineralization, and control of bone cell differentiation and bone development.

A variety of types of polypeptide factors may be found to modulate bone mineralization. For example extracellular matrix proteins (ECM) are an important constituent of bone. In bone, cartilage and the tissues forming the teeth, unlike those in other connective tissues, the matrices have the unique ability to become calcified. Furthermore, control of cell viability and morphogenesis is well known to be affected by appropriate contact with a wide array of ECM proteins. Thus OOM tumor produced ECM proteins could alter the natural process of bone mineral homeostasis by acting directly on bone cells. Alternatively, OOM tumor cells could produce diffusable soluble factors that regulate bone cell differentiation, growth and metabolism. Such factors also provide useful targets for development of therapeutic agents to regulate bone mineralization.

A number of serious pathological conditions are related to defects in bone mineralization. These include osteoporosis (a metabolic bone disease characterized by low bone mass and microarchitectural deterioration of bone tissue); osteomalacia (a defect in bone mineralization that occurs after the cessation of growth and involves only the bone and not the growth plate); rickets (a disorder of mineralization of the bone matrix, or osteoid, in growing bones; that involves both the growth plate (epiphysis) and newly formed trabecular and cortical bone); hypophosphatasia (a rare heritable type of rickets or osteomalacia (1 in 100,000 births) characterized by a reduction of activity of the tissue non-specific isoenzyme of alkaline phosphatase); and Fanconi syndrome and renal tubular acidosis (a generalized defect in renal proximal tubule transport capacity that includes impaired reabsorption of

glucose, phosphate, amino acids, bicarbonate, uric acid, citrate and other organic acids, and low-molecular weight proteins and that is associated with rickets and osteomalacia).

OOM tumor produced factors that are found to modulate fundamental processes involved in bone formation, mineralization and maintenance could provide useful targets to inhibit the progression of these diseases.

In addition to diseases characterized by defects in bone mineralization, pathological conditions of the bone include defects in bone remodeling such as Paget's disease, osteomyelitis, osteosarcoma and stress fracture. As in the case of defective bone mineralization, polypeptide factors identified from OOM tumor cells that directly modulate bone metabolism and bone cell development are useful targets for developing novel therapeutic agents to treat diseases characterized by alternative bone pathologies. Furthermore, in certain cases, expression of OOM tumor associated factors may be found to be diagnostic of bone disease making these genes useful markers for diagnostic tests to identify such conditions.

15 **Methods of the Invention**

This invention provides a method of modulating phosphate homeostasis in a subject by altering the activity of FRP 4 and FGF 23 or PHEX proteins or polynucleotides, within the subject. In one aspect, the activity of FRP 4 and FGF 23 is altered by delivering an effective amount of a polynucleotide selected from the group consisting of a polynucleotide encoding anti-FRP 4 and anti-FGF 23 antibody, a polynucleotide encoding anti-PHEX antibody, a polynucleotide encoding FRP 4 and FGF 23 or mutant FGF 23, a polynucleotide encoding PHEX and a polynucleotide encoding soluble PHEX.

Further provided is a method of inhibiting the activity of FGF 23, and FRP 4 proteins in a subject by delivering to the subject an effective amount of an agent selected from the group consisting of soluble PHEX protein, PHEX protein, a polynucleotide encoding soluble PHEX, a polynucleotide encoding PHEX, a polynucleotide encoding anti-FGF 23, and anti-FRP 4 antibodies, a composition comprising anti-FGF 23, and anti-FRP 4 antibodies or any agent that inhibits or decreases the protein stability of the FGF-23 protein or FRP-4 protein. This in turn, increases serum phosphate and enhances phosphate re-absorption in the subject. This method treats phosphate homeostasis-related diseases, for example, X-linked hypophosphatemia rickets, oncogenic osteomalacia, rhabdomyolysis, cardiomyopathy, tumoral calcinosis, renal failure and bone mineralization.

This invention provides a method of inhibiting the activity of FGF 23 and FRP 4 proteins in a subject by delivering to the subject an effective amount of an agent that inhibits, or decreases the protein stability of the FRP 4 protein and FGF 23 protein. By way of example, protein stability may be inhibited by a variety of methods known in the art, such as enhancing a protein's susceptibility to cleavage by a protease. Examples of such agents include, but are not limited to proteases which cleave FGF-23 and FRP-4 such as PHEX, or soluble PHEX.

Also provided is a method of inhibiting the activity of FGF 23 and FRP 4 proteins in a subject by delivering to the subject an effective amount of an agent that inhibits transcription and/or translation of FRP 4 and FGF 23 genes in the subject, or that enhances PHEX expression and/or protein levels.

Further provided is a method of enhancing the biological activity of FGF 23 and FRP 4 proteins in a subject is further provided by this invention, which in turn, reduces serum phosphate and phosphate re-absorption. An effective amount of an agent selected from the group consisting of an anti-PHEX antibody, a polynucleotide encoding an anti-PHEX antibody, a polynucleotide encoding FGF 23 or mutant FGF 23 and FRP 4 proteins and a composition comprising an effective amount of FGF 23 or mutant FGF 23 (e.g., a mutant not cleaved by PHEX) and FRP-4 proteins or an alternative substrate for PHEX are delivered to the subject to enhance the biological activity of FGF 23 and FRP 4. Alternatively, an effective amount of a PHEX enzyme inhibitor is delivered to the subject. See pages 33 to 39 of WO 00/50580 for methods for making PHEX enzyme inhibitors.

Further provided is a method of enhancing the biological activity of FGF 23 and FRP 4 proteins in a subject by delivering to the subject an effective amount of an agent that inhibits transcription and/or translation of PHEX genes in the subject or mutant FGF 23 which is not cleaved by PHEX. Such agents include, but are not limited to antisense PHEX polynucleotides and ribozymes that selectively cleave PHEX mRNA, mutant FGF 23 polypeptide and mutant FGF 23 polynucleotides.

Also provided is a method for modulating renal phosphate transport in a subject by delivering to the subject an effective amount of an agent that alters the activity of FRP 4 and FGF 23 or PHEX, to the subject. Also provided is a method of modulating renal phosphate transport by delivering to the subject an effective amount of an agent that alters the expression of FRP 4 and FGF 23 polynucleotides or PHEX polynucleotide. Examples of such agents are discussed above.

Further provided is a method of alleviating an oncogenic osteomalacia-associated symptom, by altering the expression of FRP 4 and FGF 23 polynucleotides or PHEX polynucleotide, within an OOM-associated neoplastic cell. Such symptoms include, but are not limited to hypophosphatemia, phosphaturia, low serum concentrations of 1,25-dihydroxyvitamin D, and osteomalacia.

Also provided is a method of alleviating symptoms associated with hypophosphatemia disorders, such as, but not limited to XLH or ADHR, by altering the expression of FRP 4 and FGF 23 polynucleotides or PHEX polynucleotide, within a cell associated with a hypophosphatemia disorder. Such symptoms include, but are not limited to hypophosphatemia, phosphaturia, low serum concentrations of 1,25-dihydroxyvitamin D, and osteomalacia.

As used herein, the term "elevated levels" means a greater than normal concentration of the protein or proteins systemically or locally. Methods to determine FGF 23, FRP 4 and PHEX protein levels are known in the art and include Western Blot Analysis to detect and determine protein levels and quantitative PCR or Northern Blot Analysis to detect and determine mRNA levels. These methods are well known in the art. See for example, WO 00/50580, WO 00/18954 and Shimada, et al. (2001) *PNAS Early Edition*, www.pnas.org/cgi/doi/10.1073/pnas.101545198.

In another embodiment, a pharmaceutical composition comprising a PHEX and/or soluble PHEX polypeptides are delivered to a subject in an effective amount to reduce phosphate re-absorption or reduce serum phosphate levels. Preferably, the pharmaceutical composition contains a polypeptide and is capable of increasing the abnormally depressed serum phosphate levels in patients with phosphate homeostasis-related disease. Alternatively, the PHEX polypeptide-containing pharmaceutical composition further comprises active agents that promote the desired function in regulating phosphate homeostasis. Suitable active agents include, but are not limited to, enzymes or co-factors that are involved in the post-translational modification and processing of the mature FRP 4 and FGF 23 proteins, or factors responsible for decreasing the biological activity of FRP 4 and FGF 23 polypeptides in circulation and at the site of abnormal phosphate homeostasis.

Various delivery systems are known and can be used to administer a therapeutic agent, e.g., encapsulation in liposomes, microparticles, microcapsules, expression by recombinant cells, receptor-mediated endocytosis (see, e.g., Wu and Wu (1987) *J. Biol. Chem.* 262:4429-4432), construction of a therapeutic nucleic acid as part of a retroviral or other vector, etc. Methods of delivery include but are not limited to transdermally, gene

therapy, intra-arterial, intra-muscular, intravenous, intranasal, and oral routes, and include sustained delivery systems. In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, by injection, or by means of a catheter or targeted gene delivery of the sequence coding for the therapeutic.

The pharmaceutical compositions identified herein as effective for their intended purpose can be administered to subjects or individuals susceptible to or at risk of developing diseases associated with abnormal phosphate transport in the kidney. When the agent is administered to a subject such as a mouse, a rat or a human patient, the agent can be added to a pharmaceutically acceptable carrier and systemically or topically administered to the subject. Therapeutic amounts can be empirically determined and will vary with the pathology being treated, the subject being treated and the efficacy and toxicity of the agent.

Administration *in vivo* can be effected in one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the composition used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician. Suitable dosage formulations and methods of administering the agents can be found below.

The agents and compositions useful for practicing the methods of the present invention can be used in the manufacture of medicaments and for the treatment of humans and other animals by administration in accordance with conventional procedures, such as an active ingredient in pharmaceutical compositions. The pharmaceutical compositions can be administered orally, intranasally, parenterally, transdermally or by inhalation therapy, and may take the form of tablets, lozenges, granules, capsules, pills, ampoules, suppositories or aerosol form. They may also take the form of gene therapy, suspensions, solutions and emulsions of the active ingredient in aqueous or nonaqueous diluents, syrups, granulates or powders. In addition to an agent of the present invention, the pharmaceutical compositions can be combined with other therapeutically useful agents.

Expression Analysis

The present invention also provides methods for detecting a cell expressing a polypeptide encoded by the FRP 4 and FGF 23 or PHEX genes by contacting a suitable

sample with suitable polynucleotide probes under conditions of moderate hybridization stringency and detecting any complementary nucleotides, thereby detecting the cell.

A suitable polynucleotide probe can be derived from the sequence of the FRP 4 and FGF 23 cDNA shown in SEQ ID NOS 1 and 3 or PHEX sequences shown in SEQ ID NO. 5
5 by preparing an oligonucleotide or polynucleotide molecule that is complementary to a portion of the cDNAs. An oligonucleotide probe ranging in size from 10 or 20 nucleotides to about 50 nucleotides can be produced using an automated DNA synthesizer. Alternatively, polynucleotide probes can be prepared from an isolated polynucleotide that comprises the FRP 4 and FGF 23 or PHEX cDNA sequence using methods well known in the art such as
10 PCR or nick translation using various DNA polymerase enzymes. Such probes typically range in size from 50 to 500 base pairs in length. Suitable polynucleotide probes should not contain repeated DNA motifs and should not have high homology to genes other than the target FRP 4 and FGF 23 or PHEX sequences.

The invention further provides a method of detecting a cell expressing polypeptide
15 encoded by the FRP 4 and FGF 23 or PHEX gene(s) by performing RT-PCR on a suitable sample using a primer pair derived from the FRP 4 and FGF 23 or a PHEX cDNA sequence. RT-PCR can be performed using methods well established in the art. A suitable primer pair will be oligonucleotides of similar annealing temperatures that are complementary to sequences on opposite strands of the FRP 4 and FGF 23 or PHEX cDNA. The primers
20 should amplify a portion of the FRP 4 and FGF 23 or PHEX cDNA ranging from 50 to 1,000 base pairs, preferably 250 to 750 base pairs in length. Optimal conditions for performing PCR can be determined without undue experimentation by comparing a series of alternative reaction conditions in which reaction conditions such as primer concentration, magnesium concentration, annealing temperature and cycle number are varied, to identify appropriate
25 PCR conditions.

Methods of detecting and monitoring FRP 4 and FGF 23 or PHEX expression are useful for detecting a neoplastic cell associated with oncogenic osteomalacia. A suitable sample for such analysis can be obtained from a tissue sample removed from subject. When practiced *in vivo*, the methods are useful for localizing an osteogenic osteomalacia inducing
30 tumor. The methods of detecting FRP 4 and FGF 23 or PHEX expression levels can be used to quantitate FRP 4 and FGF 23 or PHEX expression levels. Furthermore, it is useful to compare the level of FRP 4 and FGF 23 or PHEX expression in normal and diseased cells to determine levels of expression that are indicative of abnormal phosphate metabolism. Thus the present invention envisions using these methods to identify subjects that are appropriate

candidates for treatment using the methods of this invention. Finally, the methods of detecting FRP 4 and FGF 23 or PHEX genes expression are also useful for monitoring the efficiency of a gene delivery vehicle comprising the FRP 4 and FGF 23 or PHEX genes sequence when such a gene delivery vehicle is administered to a subject.

5 **Modulating the Phenotype of a Cell**

The present invention further provides a method for modulating the phenotype of a neoplastic cell associated with oncogenic osteomalacia comprising delivering an agent that alters the expression of polynucleotides encoding FRP 4 and FGF 23 polypeptides or PHEX polypeptides. Appropriate subjects for receiving such an agent can be identified by
10 performing the FRP 4, FGF 23 or PHEX gene expression analysis detecting the level of the proteins methods described above.

The present invention also provides a method for modulating the phenotype of a neoplastic cell associated with oncogenic osteomalacia comprising delivering an agent that alters the level of the FRP 4 and FGF 23 polypeptides or PHEX polypeptides or alters the
15 stability of the FRP 4 and FGF 23 polypeptides or PHEX polypeptides or modulates the activity of FRP 4 and FGF 23 polypeptides or PHEX polypeptides.

In addition, the invention provides methods for modulating the phenotype of a cell associated with phosphate homeostasis comprising delivering an agent that alters the expression of the FRP 4 and FGF 23 or PHEX gene(s). This method is useful for modulating
20 FRP 4 and FGF 23 or PHEX expression or activity and phosphate homeostasis in a subject. Agents that enhance the expression or activity of FRP 4 and FGF 23 are useful for reducing the re-absorption of phosphate in the kidney and serum phosphate levels while agents that inhibits the expression or activity of FRP 4 and FGF 23 are useful for increasing phosphate re-absorption, and serum phosphate levels. These agents include but are not limited to PHEX
25 polynucleotides or proteins.

The present invention further provides a method for modulating the phenotype of a cell associated with phosphate homeostasis comprising delivering an agent that alters the level of the FRP 4 and FGF 23 polypeptides or PHEX polypeptides or alters the stability of the FRP 4 and FGF 23 polypeptides or PHEX polypeptides or modulates the activity of FRP
30 4 and FGF 23 polypeptides or PHEX polypeptides.

Screening Assays

The present invention provides methods for screening various agents that modulate the expression of the FRP 4 and FGF 23 genes or PHEX gene or the activity of the FRP 4 and FGF 23 proteins or PHEX protein. These agents are useful for modulating phosphate homeostasis in a subject, for modulating renal phosphate transport, or alleviating the symptoms associated with oncogenic osteomalacia, for treating phosphate homeostasis-related disease and for altering the phenotype of a neoplastic cell associated with oncogenic osteomalacia or a cell associated with phosphate homeostasis or bone mineralization. For the purposes of this invention, an "agent" is intended to include, but not be limited to a biological or chemical compound such as a simple or complex organic or inorganic molecule, a peptide, a protein (e.g. antibody), a polynucleotide (e.g. anti-sense) or a ribozyme. A vast array of compounds can be synthesized, for example polymers, such as polypeptides and polynucleotides, and synthetic organic compounds based on various core structures, and these are also included in the term "agent". In addition, various natural sources can provide compounds for screening, such as plant or animal extracts, and the like. It should be understood, although not always explicitly stated that the agent is used alone or in combination with another agent, having the same or different biological activity as the agents identified by the inventive screen.

One preferred embodiment is a method for screening small molecules capable of interacting with the FRP 4 and FGF 23 polypeptides or mutant FGF 23 or PHEX polypeptides produced from a neoplastic cell associated with oncogenic osteomalacia. For the purpose of this invention, "small molecules" are molecules having low molecular weights (MW) that are, in one embodiment, capable of binding to a protein of interest such as FRP 4 and FGF 23 or PHEX polypeptides, and thereby altering the function of the protein. In another embodiment the small molecule may directly or indirectly modulate the stability of the proteins of interest. Preferably, the MW of a small molecule is no more than 1,000. Methods for screening small molecules capable of altering protein function are known in the art. For example, a miniaturized arrayed assay for detecting small molecule-protein interactions in cells is discussed by You et al. (1997) Chem. Biol. 4:961-968.

To practice the screening method *in vitro*, suitable cell cultures or tissue cultures containing this type of neoplastic cell are first provided. The cell can be a cultured cell or a genetically modified cell in which FRP 4 and FGF 23 or mutant FGF 23 or PHEX, or its complement is expressed. Alternatively, the cells can be from a tissue biopsy. The cells are

cultured under conditions (temperature, growth or culture medium and gas (CO₂)) and for an appropriate amount of time to attain exponential proliferation without density dependent constraints. It also is desirable to maintain an additional separate cell culture; one that does not receive the agent being tested as a control.

5 As is apparent to one of skill in the art, suitable cells may be cultured in microtiter plates and several agents may be assayed at the same time by noting genotypic changes, phenotypic changes or cell death.

 When the agent is a composition other than a DNA or RNA, such as a small molecule as described above, the agent may be directly added to the cell culture or added to culture
10 medium for addition. As is apparent to those skilled in the art, an "effective" amount must be added which can be empirically determined. When the agent is a polynucleotide, it may be directly added by use of a gene gun or electroporation. Alternatively, it may be inserted into the cell using a gene delivery vehicle or other method as described herein.

 Kits containing the agents and instructions necessary to perform the screen and *in*
15 *vitro* method as described herein also are claimed.

 The assays also can be performed in a subject. When the subject is an animal such as a rat, mouse or simian, the method provides a convenient animal model system that can be used prior to clinical testing of an agent. In this system, a candidate agent is a potential drug if transcript expression is altered, i.e., upregulated (such as restoring tumor suppressor
20 function), downregulated or eliminated as with drug resistant genes or oncogenes, or if symptoms associated or correlated to the presence of cells containing transcript expression are ameliorated, each as compared to untreated, animal having the pathological cells. In this system a candidate agent is also a potential drug for diseases associated with decreased phosphate re-absorption or decreased serum phosphate if it modulates the activity of FGF-23
25 or FRP-4, by for example, inhibiting protein stability.

 It also can be useful to have a separate negative control group of cells or animals which are healthy and not treated, which provides a basis for comparison. After administration of the agent to subject, suitable cells or tissue samples are collected and assayed for altered gene expression or protein function.

30 **Polynucleotides**

 An isolated polynucleotide encoding FRP 4 and FGF 23 or mutant FGF 23, PHEX as well as antibodies that specifically recognize and bind these proteins are provided by this invention. Polynucleotides comprising the sequence of the FRP 4 and FGF 23 or mutant FGF

23 or PHEX genes are useful for practicing various embodiments of the present invention. Polynucleotides comprising the sequence of the PHEX gene also is useful for practicing various embodiments of the present invention.

These polynucleotides include, but are not limited to probes for detecting and
5 monitoring gene expression, primers for performing polymerase chain reaction (PCR), cDNA molecules encoding one or more of polypeptide selected from the group consisting of FRP 4, FGF 23, mutant FGF 23, soluble PHEX and PHEX, antibodies that specifically recognize and bind these proteins, gene delivery vehicles to deliver the polynucleotides to a cell, expression
10 vectors for the production of the protein products, and anti-sense polynucleotides and ribozymes to modulate expression of a protein selected from the group consisting of FRP 4, FGF 23, mutant FGF 23, soluble PHEX and PHEX as well as antibodies that specifically recognize and bind these proteins.

The sequences of cDNAs encoding these proteins are provided in SEQ ID NOS. 1, 3 and 5, respectively. Three embodiments of mutant FGF 23 are provided in Nature (2000)
15 26:345-348. One of skill in the art will be familiar with a variety of means by which to detect and obtain such an isolated polynucleotide. Descriptions of several of these methods are provided below.

In addition to the sequence shown in SEQ ID NOS. 1, 3, and 5, the methods of this invention can be practiced using anti-sense polynucleotides, e.g. antisense RNA,
20 complementary to this sequence. One can obtain an antisense RNA using the sequence provided in SEQ ID NOS. 1, 3, and 5 and the methodology described in Vander Krol, et al. (1988) *BioTechniques* 6:958.

The polynucleotides can be introduced by any suitable gene delivery method or vector. They also can be expressed in a suitable host cell for generating a cell-based therapy.
25 These methods are described in more detail below.

This invention can also utilize genetically modified cells that produce enhanced expression of one or more polypeptides selected from the group consisting of FRP 4, FGF 23, mutant FGF 23 soluble PHEX and PHEX, as compared to wild-type cells. The genetically modified cells can be produced by insertion of upstream regulatory sequences such as
30 promoters or gene activators (see U.S. Patent No. 5,733,761).

The polynucleotides and sequences identified above can be conjugated to a detectable marker, e.g., an enzymatic label or a radioisotope for detection of nucleic acid and/or expression of the gene in a cell. A wide variety of appropriate detectable markers are known in the art, including fluorescent, radioactive, enzymatic or other ligands, such as

avidin/biotin, which are capable of giving a detectable signal. In preferred embodiments, one will likely desire to employ a fluorescent label or an enzyme tag, such as urease, alkaline phosphatase or peroxidase, instead of radioactive or other environmentally undesirable reagents. In the case of enzyme tags, colorimetric indicator substrates are known which can be employed to provide a means visible to the human eye or spectrophotometrically, to identify specific hybridization with complementary nucleic acid-containing samples. Briefly, this invention further provides a method for detecting a single-stranded polynucleotide encoding a protein selected from the group consisting of FRP 4, FGF 23, mutant FGF 23, and PHEX, or its complement(s), by contacting target single-stranded polynucleotides with a labeled, single-stranded polynucleotide (a probe) which is a portion of the nucleotides shown in SEQ ID NOS. 1, 3, or 5, or a polynucleotide encoding a protein as shown in SEQ ID NOS. 2, 4, or 6 (or the corresponding complements) under conditions permitting hybridization (preferably moderately stringent hybridization conditions) of complementary single-stranded polynucleotides, or more preferably, under highly stringent hybridization conditions. Hybridized polynucleotide pairs are separated from un-hybridized, single-stranded polynucleotides. The hybridized polynucleotide pairs are detected using methods well known to those of skill in the art and set forth, for example, in Sambrook, et al. (1989) *supra*.

In an another aspect of this invention, the isolated polynucleotide encodes an oncogenic osteomalacia-related polypeptide, the polypeptide having one or more of the sequences shown in SEQ ID NOS: 2, 4, or 6, or an analog thereof having conservative amino acid substitutions. In a further aspect, the isolated polynucleotide of this invention encodes oncogenic osteomalacia-related mutein polypeptide, the mutein polypeptide having the amino acid sequence of one or more of SEQ ID NOS: 2, 4, or 6, or an analog thereof having non-conservative amino acid substitutions.

Obtaining the Polynucleotides and Proteins To Practice the Invention

The polynucleotides and sequences used to practice the methods of this invention can be obtained using chemical synthesis, recombinant cloning methods, PCR, or any combination thereof. Methods of chemical polynucleotide synthesis are well known in the art and need not be described in detail herein. One of skill in the art can use the sequence data provided herein to obtain a desired polynucleotide by employing a DNA synthesizer or ordering from a commercial service.

Compositions containing the polynucleotides and sequences encoding one or more of the FRP 4, FGF 23, mutant FGF 23 and/or PHEX and soluble PHEX proteins, as well as the antibodies that specifically recognize and bind these proteins and polypeptides, in isolated form or contained within a vector or host cell may be delivered. When these compositions
5 are to be used pharmaceutically, they are combined with a pharmaceutically acceptable carrier.

Suitable cell or tissue samples used for the methods of this invention encompass body fluid, solid tissue samples, tissue cultures or cells derived therefrom and the progeny thereof, and sections or smears prepared from any of these sources, or any other samples that may
10 contain a neoplastic tumor tissue.

Polynucleotides of the invention can be isolated using the techniques described herein or replicated using PCR. The PCR technology is the subject matter of United States Patent Nos. 4,683,195, 4,800,159, 4,754,065, and 4,683,202 and described in PCR: THE
POLYMERASE CHAIN REACTION (Mullis et al. eds, Birkhauser Press, Boston (1994)) or
15 MacPherson, et al. (1991) and (1994), *supra*, and references cited therein. Alternatively, one of skill in the art can use the sequences provided herein and a commercial DNA synthesizer to replicate the DNA. Still further, one of skill in the art can insert the polynucleotide into a suitable replication vector and insert the vector into a suitable host cell (prokaryotic or eukaryotic) for replication and amplification. The DNA so amplified can be isolated from the
20 cell by methods well known to those of skill in the art. A process for obtaining polynucleotides by this method is further provided herein as well as the polynucleotides so obtained.

RNA can be obtained by first inserting a DNA polynucleotide into a suitable host cell. The DNA can be inserted by any appropriate method, e.g., by the use of an appropriate gene
25 delivery vehicle (e.g., liposome, plasmid or vector) or by electroporation. When the cell replicates and the DNA is transcribed into RNA; the RNA can then be isolated using methods well known to those of skill in the art, for example, as set forth in Sambrook, et al. (1989) *supra*. For instance, mRNA can be isolated using various lytic enzymes or chemical solutions according to the procedures set forth in Sambrook, et al. (1989), *supra* or extracted by
30 nucleic-acid-binding resins following the accompanying instructions provided by manufactures.

Polynucleotides exhibiting sequence complementarity or homology to one or more of SEQ ID NOS. 1, 3, or 5, find utility as hybridization probes. Since the full coding sequence

of the transcript is known, any portion of this sequence or homologous sequences, can be used in the methods of this invention.

It is known in the art that a "perfectly matched" probe is not needed for a specific hybridization. Minor changes in probe sequence achieved by substitution, deletion or
5 insertion of a small number of bases do not affect the hybridization specificity. In general, as much as 20% base-pair mismatch (when optimally aligned) can be tolerated. Preferably, a probe useful for detecting the aforementioned mRNA is at least about 80% identical to the homologous region. More preferably, the probe is 85% identical to the corresponding gene sequence after alignment of the homologous region; even more preferably, it exhibits 90%
10 identity.

These probes can be used in radioassays (*e.g.* Southern and Northern blot analysis) to detect, prognose, diagnose or monitor various neoplastic cells or tumor tissues containing these cells. The probes also can be attached to a solid support or an array such as a chip for use in high throughput screening assays for the detection of expression of the gene
15 corresponding a polynucleotide of this invention. Accordingly, this invention also provides a probe comprising or corresponding to one or more polynucleotides selected from the group consisting of SEQ ID NOS. 1, 3, or 5 or its complement, or a fragment thereof as well as one or more polynucleotides selected from the group consisting of SEQ ID NOS. 2, 4, or 6, attached to a solid support for use in high throughput screens.

20 The total size of fragment, as well as the size of the complementary stretches, will depend on the intended use or application of the particular nucleic acid segment. Smaller fragments will generally find use in hybridization embodiments, wherein the length of the complementary region may be varied, such as between at least 5 to 10 to about 100 nucleotides, or even full length according to the complementary sequences one wishes to
25 detect.

Nucleotide probes having complementary sequences over stretches greater than 5 to 10 nucleotides in length are generally preferred, so as to increase stability and selectivity of the hybrid, and thereby improving the specificity of particular hybrid molecules obtained. More preferably, one can design polynucleotides having gene-complementary stretches of 10
30 or more or more than 50 nucleotides in length, or even longer where desired. Such fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, by application of nucleic acid reproduction technology, such as the PCR technology with two priming oligonucleotides as described in U.S. Pat. No. 4,603,102 or by introducing

selected sequences into recombinant vectors for recombinant production. A preferred probe is about 50-75 or more preferably, 50-100, nucleotides in length.

The polynucleotides described herein can serve as primers for the detection of genes or gene transcripts that are expressed in neoplastic cells associated with oncogenic osteomalacia. In this context, amplification means any method employing a primer-dependent polymerase capable of replicating a target sequence with reasonable fidelity. Amplification may be carried out by natural or recombinant DNA-polymerases such as T7 DNA polymerase, Klenow fragment of *E.coli* DNA polymerase, and reverse transcriptase. A preferred length of the primer is the same as that identified for probes, above.

10 A preferred amplification method is PCR. However, PCR conditions used for each reaction are empirically determined. A number of parameters influence the success of a reaction. Among them are annealing temperature and time, extension time, Mg^{2+} concentration, pH, and the relative concentration of primers, templates, and deoxyribonucleotides. After amplification, the resulting DNA fragments can be detected by
15 agarose gel electrophoresis followed by visualization with ethidium bromide staining and ultraviolet illumination.

The methods of the invention can also employ the isolated polynucleotide encoding the proteins described herein operatively linked to a promoter of RNA transcription, as well as other regulatory sequences for replication and/or transient or stable expression of the DNA
20 or RNA. As used herein, the term "operatively linked" means positioned in such a manner that the promoter will direct transcription of RNA off the DNA molecule. Examples of such promoters are SP6, T4 and T7. In certain embodiments, cell-specific promoters are used for cell-specific expression of the inserted polynucleotide. Vectors which contain a promoter or a promoter/enhancer, with termination codons and selectable marker sequences, as well as a
25 cloning site into which an inserted piece of DNA can be operatively linked to that promoter are well known in the art and commercially available. For general methodology and cloning strategies, see GENE EXPRESSION TECHNOLOGY (Goeddel ed., Academic Press, Inc. (1991)) and references cited therein and VECTORS: ESSENTIAL DATA SERIES (Gacsa and Ramji, eds., John Wiley & Sons, N.Y. (1994)), which contains maps, functional properties, commercial
30 suppliers and a reference to GenEMBL accession numbers for various suitable vectors. Preferable, these vectors are capable of transcribing RNA *in vitro* or *in vivo*.

Expression vectors containing these nucleic acids are useful to obtain host vector systems to produce proteins and polypeptides. It is implied that these expression vectors must be replicable in the host organisms either as episomes or as an integral part of the

chromosomal DNA. Suitable expression vectors include plasmids, viral vectors, including adenoviruses, adeno-associated viruses, retroviruses, cosmids, etc. Adenoviral vectors are particularly useful for introducing genes into tissues *in vivo* because of their high levels of expression and efficient transformation of cells both *in vitro* and *in vivo*. When a nucleic acid is inserted into a suitable host cell, e.g., a prokaryotic or a eukaryotic cell and the host cell replicates, the protein can be recombinantly produced. Suitable host cells will depend on the vector and can include mammalian cells, animal cells, human cells, simian cells, insect cells, yeast cells, and bacterial cells constructed using well known methods. See Sambrook, et al. (1989) *supra*. In addition to the use of viral vector for insertion of exogenous nucleic acid into cells, the nucleic acid can be inserted into the host cell by methods well known in the art such as transformation for bacterial cells; transfection using calcium phosphate precipitation for mammalian cells; or DEAE-dextran; electroporation; or microinjection. See Sambrook, et al. (1989) *supra* for this methodology. Thus, this invention also provides a host cell, e.g. a mammalian cell, an animal cell (rat or mouse), a human cell, or a procaryotic cell such as a bacterial cell, containing a polynucleotide encoding a protein or polypeptide or antibody.

When the vectors are used for gene therapy *in vivo* or *ex vivo*, a pharmaceutically acceptable vector is preferred, such as a replication-incompetent retroviral or adenoviral vector. Pharmaceutically acceptable vectors containing the nucleic acids of this invention can be further modified for transient or stable expression of the inserted polynucleotide. As used herein, the term "pharmaceutically acceptable vector" includes, but is not limited to, a vector or delivery vehicle having the ability to selectively target and introduce the nucleic acid into dividing cells. An example of such a vector is a "replication-incompetent" vector defined by its inability to produce viral proteins, precluding spread of the vector in the infected host cell. An example of a replication-incompetent retroviral vector is LNL6 (Miller, A.D. et al. (1989) *BioTechniques* 7:980-990). The methodology of using replication-incompetent retroviruses for retroviral-mediated gene transfer of gene markers is well established (Correll, et al. (1989) *PNAS USA* 86:8912; Bordignon (1989) *PNAS USA* 86:8912-52; Culver, K. (1991) *PNAS USA* 88:3155; and Rill, D.R. (1991) *Blood* 79(10):2694-700. Clinical investigations have shown that there are few or no adverse effects associated with the viral vectors, see Anderson (1992) *Science* 256:808-13.

Compositions containing the polynucleotides of this invention, in isolated form or contained within a vector or host cell are further provided herein. When these compositions are to be used pharmaceutically, they are combined with a pharmaceutically acceptable carrier.

Proteins

This invention provides uses for one or more protein selected from the group consisting of FRP 4, FGF 23, mutant FGF 23, and PHEX and soluble PHEX polypeptides expressed from the polynucleotides described above, which is intended to include wild-type
5 and recombinantly produced polypeptides and proteins from prokaryotic and eukaryotic host cells, as well as muteins, analogs and fragments thereof. In some embodiments, the term also includes antibodies and anti-idiotypic antibodies. In one embodiment, these proteins or polypeptides are a phosphatonin-related factor which modulates phosphatonin activity, an example of which is PHEX. Such polypeptides can be isolated or produced using the
10 methods identified below.

It is understood that functional equivalents or variants of the wild-type polypeptide or protein also are within the scope of this invention, for example, those having conservative amino acid substitutions. Other analogs include fusion proteins comprising a protein or polypeptide.

15 The proteins and polypeptides described herein are obtainable by a number of processes well known to those of skill in the art, which include purification, chemical synthesis and recombinant methods. Full length proteins can be purified from a neoplastic cell or a tumor biopsy as identified above. Sources for purifying the protein can also be serum or urine samples from an individual, such as a patient with oncogenic osteomalacia.
20 Proteins can be purified by methods such as immunoprecipitation with antibody, and standard techniques such as gel filtration, ion-exchange, reversed-phase, and affinity chromatography using a fusion protein as shown herein. For such methodology, see for example Deutscher et al. (1999) GUIDE TO PROTEIN PURIFICATION: METHODS IN ENZYMOLOGY (Vol. 182, Academic Press). Accordingly, this invention also provides the processes for obtaining these
25 proteins and polypeptides as well as the products obtainable and obtained by these processes.

The proteins and polypeptides also can be obtained by chemical synthesis using a commercially available automated peptide synthesizer such as those manufactured by Perkin Elmer/Applied Biosystems, Inc., Model 430A or 431A, Foster City, CA, USA. The synthesized protein or polypeptide can be precipitated and further purified, for example by
30 high performance liquid chromatography (HPLC). Accordingly, this invention also provides a process for chemically synthesizing the proteins of this invention by providing the sequence of the protein and reagents, such as amino acids and enzymes and linking together the amino acids in the proper orientation and linear sequence.

Alternatively, the proteins and polypeptides can be obtained by well-known recombinant methods as described, for example, in Sambrook, et al., (1989), supra, using the host cell and vector systems described above.

Also provided by this application are the polypeptides and proteins described herein
5 conjugated to a detectable agent for use in the diagnostic methods. For example, detectably labeled proteins and polypeptides can be bound to a column and used for the detection and purification of antibodies. They also are useful as immunogens for the production of antibodies as described below. The proteins and fragments of this invention are useful in an *in vitro* assay system to screen for agents or drugs, which modulate cellular processes.

10 One or more protein selected from the group consisting of FRP 4, FGF 23, mutant FGF 23, PHEX and soluble PHEX also can be combined with various liquid phase carriers, such as sterile or aqueous solutions, pharmaceutically acceptable carriers, suspensions and emulsions. Examples of non-aqueous solvents include propyl ethylene glycol, polyethylene glycol and vegetable oils. When used to prepare antibodies, the carriers also can include an
15 adjuvant that is useful to non-specifically augment a specific immune response. A skilled artisan can easily determine whether an adjuvant is required and select one. However, for the purpose of illustration only, suitable adjuvants include, but are not limited to Freund's Complete and Incomplete, mineral salts and polynucleotides.

This invention also provides methods of using a pharmaceutical composition
20 comprising any of a protein, analog, mutein, polypeptide fragment, antibody, antibody fragment or anti-idiotypic antibody of this invention, alone or in combination with each other or other agents, and an acceptable carrier. These compositions are useful for various diagnostic and therapeutic methods as described herein.

Antibodies

25 The present invention also envisions utilizing an antibody capable of specifically forming a complex with one or more protein selected from the group consisting of FRP 4, FGF 23, mutant FGF 23, soluble PHEX and PHEX proteins or polypeptides as described above. The term "antibody" includes polyclonal antibodies and monoclonal antibodies. The antibodies include, but are not limited to mouse, rat, and rabbit or human antibodies.

30 Laboratory methods for producing polyclonal antibodies and monoclonal antibodies, as well as deducing their corresponding nucleic acid sequences, are known in the art, see Harlow and Lane (1988) supra and Sambrook, et al. (1989) supra. The monoclonal antibodies of this invention can be biologically produced by introducing protein or a fragment

thereof into an animal, e.g., a mouse or a rabbit. The antibody producing cells in the animal are isolated and fused with myeloma cells or hetero-myeloma cells to produce hybrid cells or hybridomas. Accordingly, the hybridoma cells producing the monoclonal antibodies of this invention also are provided.

5 Thus, using the protein or fragment thereof, and well known methods, one of skill in the art can produce and screen the hybridoma cells and antibodies of this invention for antibodies having the ability to bind the proteins or polypeptides.

 If a monoclonal antibody being tested binds with the protein or polypeptide, then the antibody being tested and the antibodies provided by the hybridomas of this invention are
10 equivalent. It also is possible to determine without undue experimentation, whether an antibody has the same specificity as the monoclonal antibody of this invention by determining whether the antibody being tested prevents a monoclonal antibody of this invention from binding the protein or polypeptide with which the monoclonal antibody is normally reactive. If the antibody being tested competes with the monoclonal antibody of the
15 invention as shown by a decrease in binding by the monoclonal antibody of this invention, then it is likely that the two antibodies bind to the same or a closely related epitope. Alternatively, one can pre-incubate the monoclonal antibody of this invention with a protein with which it is normally reactive, and determine if the monoclonal antibody being tested is inhibited in its ability to bind the antigen. If the monoclonal antibody being tested is
20 inhibited then, in all likelihood, it has the same, or a closely related, epitopic specificity as the monoclonal antibody of this invention.

 The term "antibody" also is intended to include antibodies of all isotypes. Particular isotypes of a monoclonal antibody can be prepared either directly by selecting from the initial fusion, or prepared secondarily, from a parental hybridoma secreting a monoclonal antibody
25 of different isotype by using the sib selection technique to isolate class switch variants using the procedure described in Steplewski et al. (1985) *PNAS* 82:8653 or Spira et al. (1984) *J. Immunol. Methods* 74:307.

 This invention also provides uses for biologically active fragments of the polyclonal and monoclonal antibodies described above. These "antibody fragments" retain some ability
30 to selectively bind with its antigen or immunogen. Such antibody fragments can include, but are not limited to: Fab; Fab'; F(ab')₂; Fv; and SCA.

 A specific example of "a biologically active antibody fragment" is a CDR region of the antibody. Methods of making these fragments are known in the art, see for example, Harlow and Lane, (1988) *supra*.

The antibodies utilized in practicing this invention also can be modified to create chimeric antibodies. Chimeric antibodies are those in which the various domains of the antibodies' heavy and light chains are coded for by DNA from more than one species making the antibody compositions more compatible with a host system by minimizing potential adverse immune system responses. This may be accomplished in a variety of ways, including modifying the antibodies to create chimeric antibodies (e.g., antibodies in which the various domains of the antibodies' heavy and light chains are coded for by DNA from more than one species), such as humanized antibodies (Oi, et al. (1986) *BioTechniques* 4(3):214). This is accomplished by removing all or a portion of the Fc portion of a foreign species antibody or using an antibody of the same species as the host animal, for example, the use of antibodies from human/human hybridomas. Humanized antibodies (i.e., non immunogenic in a human) may be produced, for example, by replacing an immunogenic portion of an antibody with a corresponding, but non immunogenic portion (i.e., chimeric antibodies). Such chimeric antibodies may contain the reactive or antigen binding portion of an antibody from one species and the Fc portion of an antibody (non immunogenic) from a different species. Examples of chimeric antibodies, include but are not limited to, non-human mammal-human chimeras, rodent-human chimeras, murine-human and rat-human chimeras (Robinson et al., International Patent Application 184,187; Taniguchi M., European Patent Application 171,496; Morrison et al., European Patent Application 173, 494; Neuberger et al., PCT Application WO 86/01533; Cabilly et al., 1987 *Proc. Natl. Acad. Sci. USA* 84:3439; Nishimura et al., 1987 *Canc. Res.* 47:999; Wood et al., 1985 *Nature* 314:446; Shaw et al., 1988 *J. Natl. Cancer Inst.* 80: 15553, all incorporated herein by reference).

General reviews of "humanized" chimeric antibodies are provided by Morrison S., 1985 *Science* 229:1202 and by Oi et al., 1986 *BioTechniques* 4:214. Suitable "humanized" antibodies can be alternatively produced by CDR or CEA substitution (Jones et al., 1986 *Nature* 321:552; Verhoeyan et al., 1988 *Science* 239:1534; Biedler et al. 1988 *J. Immunol.* 141:4053, all incorporated herein by reference).

The antibodies or antigen binding fragments may also be produced by genetic engineering. The technology for expression of both heavy and light chain genes in *E. coli* is the subject the PCT patent applications; publication number WO 901443, WO901443, and WO 9014424 and in Huse et al., 1989 *Science* 246:1275-1281. Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. 4,946,778; Bird, 1988, *Science* 242, 423-426; Huston, et al., 1988, *Proc. Natl. Acad. Sci. USA* 85, 5879-5883; and Ward, et al., 1989, *Nature* 334, 544-546) can be adapted to produce single chain antibodies.

Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

The isolation of other hybridomas secreting monoclonal antibodies with the specificity of the monoclonal antibodies of the invention can also be accomplished by one of ordinary skill in the art by producing anti-idiotypic antibodies (Herlyn, et al. (1986) *Science* 232:100). An anti-idiotypic antibody is an antibody which recognizes unique determinants present on the monoclonal antibody produced by the hybridoma of interest.

Idiotypic identity between monoclonal antibodies of two hybridomas demonstrates that the two monoclonal antibodies are the same with respect to their recognition of the same epitopic determinant. Thus, by using antibodies to the epitopic determinants on a monoclonal antibody it is possible to identify other hybridomas expressing monoclonal antibodies of the same epitopic specificity.

It is also possible to use the anti-idiotypic technology to produce monoclonal antibodies that mimic an epitope. For example, an anti-idiotypic monoclonal antibody made to a first monoclonal antibody will have a binding domain in the hypervariable region that is the mirror image of the epitope bound by the first monoclonal antibody. Thus, in this instance, the anti-idiotypic monoclonal antibody could be used for immunization for production of these antibodies.

As used in this invention, the term "epitope" is meant to include any determinant having specific affinity for the monoclonal antibodies of the invention. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.

The antibodies utilized in this invention can be linked to a detectable agent or label. There are many different labels and methods of labeling known to those of ordinary skill in the art.

The antibody-label complex is useful to detect the protein or fragments in a sample, using standard immunochemical techniques such as immunohistochemistry as described by Harlow and Lane (1988) supra. Competitive and non-competitive immunoassays in either a direct or indirect format are examples of such assays, e.g., enzyme linked immunoassay (ELISA) radioimmunoassay (RIA) and the sandwich (immunometric) assay. Those of skill in the art will know, or can readily discern, other immunoassay formats without undue experimentation.

The coupling of antibodies to low molecular weight haptens can increase the sensitivity of the assay. The haptens can then be specifically detected by means of a second reaction. For example, it is common to use haptens such as biotin, which reacts avidin, or dinitropherry, pyridoxal, and fluorescein, which can react with specific anti-hapten
5 antibodies. See Harlow and Lane (1988) *supra*.

Monoclonal antibodies also can be bound to many different carriers. Thus, this invention also envisions employing compositions containing the antibodies and another substance, active or inert. Examples of well-known carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses,
10 polyacrylamides, agaroses and magnetite. The nature of the carrier can be either soluble or insoluble for purposes of the invention. Those skilled in the art will know of other suitable carriers for binding monoclonal antibodies, or will be able to ascertain such, using routine experimentation.

See also WO 00/18954, WO 0050580 and Shimada et al. (2001) *PNAS Early Edition*,
15 www.pnas.org/cgi/doi/10.1073/pnas.101545198 for method for making antibodies useful in the methods of this invention.

Compositions containing the antibodies, fragments thereof or cell lines which produce the antibodies, are encompassed by this invention. When these compositions are to be used pharmaceutically, they are combined with a pharmaceutically acceptable carrier.

20 Cells

The invention provides methods for identification, characterization and modulation of a selected phenotype of a tumor mass isolated from a patient with oncogenic osteomalacia. Manipulation of selected cells is useful for practicing these methods of the invention.

Tumors from which sample cells can be obtained for use in the present invention are
25 tumors originated from patients with symptoms of oncogenic osteomalacia. These include, but are not limited to, hemangiopericytomas and other tumors of mesenchymal origin, carcinoma of prostate and lung, fibrous dysplasia of bone, linear sebaceous naevus syndrome, neurofibromatosis, and oat cell carcinoma.

Tumor cells are typically obtained from a cancer patient by resection, biopsy, or
30 endoscopic sampling; the cells may be used directly, stored frozen, or maintained or expanded in culture. Samples of both the tumor and the patient's blood or blood fraction should be thoroughly tested to ensure sterility before co-culturing of the cells. Standard sterility tests are known to those of skill in the art and are not described in detail herein. The

tumor cells can be cultured *in vitro* to generate a cell line. Conditions for reliably establishing short-term cultures and obtaining at least 10^8 cells from a variety of tumor types is described in Dillmar, et al. (1993) *J. Immunother.* 14:65-69. Alternatively, tumor cells can be dispersed from, for example, a biopsy sample, by standard mechanical means before use.

5 One aspect of the invention involves the comparison of transcript expression pattern between a sample cell and a control cell. The selection of the control cell is determined by the sample cell initially selected and the phenotype of interest. The control cell can be any of a counterpart normal cell type, a counterpart benign cell type, a counterpart non-neoplastic cell type and a non-neoplastic precursor of the neoplastic cell. For example, the sample cell
10 can be a hemangiopericytoma cell isolated from a patient with oncogenic osteomalacia; the counterpart control cell can be a hemangiopericytoma cell isolated from a patient who does not have oncogenic osteomalacia.

 Conditions for reliably establishing short-term cultures and obtaining at least 10^8 cells from a variety of tumor types is described in Dillmar, et al. (1993) *J. Immunother.* 14:65-69.
15 Alternatively, tumor cells can be dispersed from, for example, a biopsy sample, by standard mechanical means before use.

 One aspect of the invention involves the comparison of transcript expression pattern between a sample cell and a control cell. The selection of the control cell is determined by the sample cell initially selected and the phenotype of interest. The control cell can be any of
20 a counterpart normal cell type, a counterpart benign cell type, a counterpart non-neoplastic cell type and a non-neoplastic precursor of the neoplastic cell. For example, the sample cell can be a hemangiopericytoma cell isolated from a patient with oncogenic osteomalacia; the counterpart control cell can be a hemangiopericytoma cell isolated from a patient who does not have oncogenic osteomalacia.

25 **Identification, analysis, and manipulation of genetic polymorphisms with SNP technology**

 An isolated gene of one or more of a gene selected from the group consisting of FRP 4, FGF 23, soluble PHEX and PHEX genes can be used to search for and identify single nucleotide polymorphisms (SNP's), which are mutant variants of the gene in the human
30 population. Identification of such polymorphisms is useful to define human diseases to which mutations in the genes contribute and to perfect therapies for disease processes in which the protein encoded by the genes participates. Mutant variants of the genes identified in this manner can then be employed in the development, screening, and analysis of

pharmaceutical agents to treat these diseases. Methods to detect such SNP's can be formatted to create diagnostic tests. Furthermore, various mutations in the gene which effect the response of different individuals to therapeutic agents can be identified and then diagnosed through analysis of SNP's, to guide the prescription of appropriate treatments. Also, SNP's
5 identified in the genes can provide useful sequence markers for genetic tests to analyze other genes and mutations in the region of the genome where the gene(s) is located. Thus it is useful to incorporate these SNP's into polymorphism databases.

Skilled practitioners of the art are familiar with an array of methods for identifying and analyzing SNP's. High throughput DNA sequencing procedures such as sequencing by
10 hybridization (Drmanac et al. (1993) *Science* 260:1649-52), minisequencing primer extension (Syvanen, (1999) *Hum. Mutat.* 13(1):1-10), or other sequencing methods can be used to detect SNP's in defined regions of the gene. Alternatively, hybridization to oligonucleotides on DNA microarrays (Lipshutz et al. (1999) *Nat. Genet.* 21(1 Suppl.):20-4) analysis of single
15 strand conformational polymorphisms in DNA or RNA molecules by various analytical methods (Nataraj (1999 Wiley & Sons, United Kingdom) pp:277-297; Dorin et al. (1992) *Nature* 359:211-215) and *Electrophoresis* 20(6):1177-85), PCR-based mutational analyses such as PCR with primers spanning the polymorphic sequence, or protection of SNP-containing oligonucleotides from nuclease protection such as by use of the bacterial mutS
20 protein can be employed. Many sophisticated high-throughput technologies based on methods such as automated capillary electrophoresis (Larsen et al. (1999) *Hum. Mutat.* 13(4):318-27), time-of-flight mass spectroscopy (Li et al. (1999) *supra*, high density microarrays (Sapolsky et al. (1999) *Genet. Anal.* 14(5-6):187-92), semiconductor microchips (Gilles et al. (1999) *Nat. Biotechnol.* 17(4):365-70), and others have been demonstrated that can be employed with the gene(s) to perform the uses described above.

25 All references, patents and patent publications are incorporated into by reference into this application.

The following examples are intended to illustrate, but not limit this invention.

30 MATERIALS AND METHODS

Criteria for Tumor Selection. OOM tumors included in this study were resected from patients who met the following criteria: 1) acquired hypophosphatemia with no family history of hypophosphatemia or other medical illnesses predisposing to hypophosphatemia 2) low serum 1,25 (OH)₂ vitamin D₃ 3) inappropriate phosphaturia (suppressed tubular

reabsorption of phosphate (TRP)) 4) evidence of osteomalacia 5) normalization of biochemical parameters after tumor resection 6) tumor type previously reported to be associated with OOM (Table 1).

Table 1

1.	Patient	Phosphorous 2.5-4.5 mg/dl	Calcium 8.5-10.5 mg/dl	Intact PTH 10-65 pg/ml	1,25(OH) ₂ D ₃ 18-66 pg/ml	TRP %
Hp1	Pre-Op	1.4	9.7	37		43
	Post-Op	2.9	9.8	42	31	69
Hp2	Pre-Op	1.5	9.9	144	13	58
	Post-Op	4.0	9.6	61	29	85
Hp3**	Pre-Op	1.1	5.1		<10	19
	Post-Op	2.5				
Hp4	Pre-Op	1.3	9.1	45	12	42
	Post-Op	3.9	9.0	27	110	91
S1	Pre-Op	1.2	9.0	35		65
	Post-Op	3.2		2		

* Conditioned media from tumor cells inhibits phosphate transport in opossum kidney cell assay

Tumor persists

Mesenchymal tumors selected as control tumors were obtained from the John Hopkins Hospital Tumor Bank (Table 2). None of tumors were obtained from patients with hypophosphatemia. The two control hemangiopericytomas that were selected for SAGE libraries had similar histological appearance and were derived from similar anatomical locations as OOM tumors. An additional four control mesenchymal tumors were selected for microarray analysis. These included three additional hemangiopericytomas isolated from the chest (C3). Brain (C5), and lower extremity (C6) and one tumor defined as a mesenchymal tumor isolated from the pancreas (C4) (Table 2).

Table 2

Tumor	OOM	Pathology	Location	Analyses
Hp1	Yes	Hemangiopericytoma	Lower extremity	SAGE, MA
Hp2	Yes	Hemangiopericytoma	Sinonasal	SAGE, MA
Hp3	Yes	Hemangiopericytoma	Meninges	SAGE
Hp4	Yes	Hemangiopericytoma	Upper extremity	MA
S1	Yes	Leiomyosarcoma	Upper extremity	SAGE
C1	No	Hemangiopericytoma	Sinonasal	SAGE, MA
C2	No	Hemangiopericytoma	Nasopharyngeal	SAGE
C3	No	Hemangiopericytoma	Chest	MA
C4	No	Mesenchymal tumor	Pancreas	MA
C5	No	Hemangiopericytoma	Brain	MA
C6	No	Hemangiopericytoma	Lower extremity	MA

Tissue RNA Extraction. Tissues were obtained immediately after surgical resection and frozen in liquid nitrogen and stored at -80°C . Tissue samples (0.5-1.0 gram) were diced into small fragments with a sterile scalpel and homogenized in Trizol (Life Technologies, Gaithersburg, MD). Total cytoplasmic RNA was extracted in Trizol or Stat-100 (Biotecx Laboratories, Inc., Houston, TX), according to the directions of the manufacturer. Poly (A)+ RNA was extracted using the Oligotex mRNA Midi Kit (Qiagen Inc., CA).

10

SAGE Analysis. SAGE analysis was performed as described previously (Velculescu, et al. (1995) *Science* 270:484-487). The sequence and abundance of each of the transcript tags were determined by SAGE software as described previously (Hibi et al. (1998) *Cancer Res.* 8:67-113. Micro-SAGE analysis was performed on tumor Hp-3 SAGE libraries were independently sequenced to the following tag depths: C-1=44559, C-2=43386, Hp-1=48210, Hp-2=43916, Hp-3 = 23066, Sp-1=22493. All values are reported after normalization to 40,000 tags. Sequence tags were represented by a 5' Nla III site followed by a unique 10 base pair sequence. For convenience, the NlaIII recognition sequence is not reported as part of the tag sequence. Table 3 lists most of the differentially expressed genes based on SAGE analysis alone.

20

Table 3

Identity	SAGE TAG	Classification	Accession Number
MEPE	AAAATAAACA	Secreted (MEPE)	NM_020203
huH1		Intracellular (huH1)	AL08006
Dentin Matrix Protein 1	ATATACCAGG	ECM	U65378
Frizzled Related Protein 4	TGCCCCCTTGC	Secreted	AF026692
Serine Protease 11	TTTCCCTCAA	Secreted	AF70555
Candidate 5	GGTAGTACCA	Novel	
CD44 variant	ATATGTATAT	ECM	Novel
TIAM-1 variant	ACGTGTCTAT	Plasma membrane	U90902
Osteopontin	AATAGAAATT	ECM	X13694
Glvr-1	TTCATTTGTC	Transporter	L20859
Synaptotagmin Related	TTAACTGTGT	Intracellular	Novel
Fibronectin	ATCTTGTTAC	ECM	K00799
Integrin Alpha 10	GGCATTGTCT	Plasma membrane	NM_0363
MFG-8	GGTTGGCAGG	Plasma membrane	NM_005928
Candidate 19	GTCAAATGGT	Novel	
Candidate 20	GGGCAGGGGA	Novel	
Neurogranin RC3	TGACTGTGCT	Intracellular	U89165
ANK-A	GTGCAGTA	Plasma Membrane	NM_01984
ANK-A variant	CTTGCGCT	Plasma Membrane	

5 **Lambda cDNA Library Construction.** Poly (A+) RNA from Hp-1 and Hp-2 were combined in equal amounts. A total of 5 µg of pooled RNA was used to generate a lambda cDNA library following the directions of the manufacturer (Stratagene catalogue # 200400).

10 **cDNA Isolation.** Partial cDNAs encompassing the 3' end of selected candidates were isolated using three independent methods. When possible, plasmids containing ESTs or full-length cDNAs representing genes identified by SAGE were purchased from commercial sources (Image Consortium or Genome Systems) and used as templates for amplification via polymerase chain reaction to create partial cDNAs. Alternatively, fragments were isolated using an anchored PCR technique that employed a forward primer complementary to the

15 SAGE tag and oligo dT as the reverse primer. In both cases, amplicons were inserted into vectors using the TA cloning kit (Invitrogen) and sequenced to confirm the identity of the amplicon. In several cases, cDNAs were isolated directly from OOM lambda phage libraries using a 15-mer oligo complimentary to the SAGE tag of interest.

Custom Array Generation and Analysis. PCR amplified cDNA target sequences were purified using QIAquick PCR purification kit or QIAquick Gel extraction kit (Qiagen, Inc., CA). Microarrays were prepared by spotting the target cDNA sequences in quadruplicate onto replicate nylon membranes (Biotrans; ICN, Costa Mesa, CA) at a concentration of 2 ng of DNA/spot using a BOMEK 2000 robot (Beckman Coulter, Inc., Fullerton, CA). For probes, poly (A)+ RNA was isolated from tumor tissue as described above. Poly (A)+ RNA was converted to cDNA and labeled with [³²P]-dCTP by reverse transcription using Superscript II RT (Life Technologies, Inc.). Hybridization intensities were quantitated on a STORM PhosphorImager (Molecular Dynamics, Sunnyvale, CA), and an average signal for each set of four targets was determined. Results of these assays are shown in Figures 1 and 2.

RT-PCR: RT-PCR was performed with 1 µg total RNA as previously described (Ringel JCEM (1998)). PCR was performed using 2 µl of cDNA in a 25 µl volume containing *Taq* polymerase buffer (1.5 mmol/L magnesium chloride), 1 mmol/L of each primer, 0.1 mmol/L of each deoxyribonucleotide triphosphate, and 2.5 U *Taq* polymerase (Perkin-Elmer, Foster City, CA). The following sets of sense and antisense primers were used for PCR: 5'GAGAAGGCAACCAAAGTGCAG3' (Seq. ID No. 7) and 5'GAAGCACTGGATCCACTTGCGGCG3' (Seq. ID No. 8) for *GNAS1*, 5'GTATGCCACAAGGGAAAGG3' (Seq. ID No. 9) and 5'TTCTATTAAAGGCTATAATG3' (Seq. ID No. 10) for *MEPE*, 5'CCAATGACTTCAGTTTCTGTT3' (Seq. ID No. 11) and 5'TAAGCTTGTCAAATTATTCTCAG3' (Seq. ID No. 12) for *FRP 4*, and 5'ATTGAGTGGATGGATGCAGGAA3' (Seq. ID No. 13) and 5'AGGAAAGGCTTCTGGAGCTC3' (Seq. ID No. 14) for *PHEX*. The PCR cycling profile consisted of an initial 15 minute denaturation at 94°C, followed by 29 cycles of annealing (50°C for *FRP-4* and *GNAS1*, 55°C for *PHEX*, 47°C for *MEPE*, 45 seconds), extension (72°C, 60 seconds) and denaturation (94°C, 20 seconds), with a final 5 minute extension. PCR reactions without added reverse transcriptase were performed in parallel to exclude DNA contamination. RT-PCR products were electrophoresed on 6% polyacrylamide gels, stained with ethidium bromide and visualized with UV light.

PHEX Assay. The ability of PHEX to enhance the degradation of candidate genes was analyzed using methods and techniques known in the art. Briefly, expression vectors containing cDNA inserts encoding PHEX, FGF23, FGF23 (R179Q), FRP4, MEPE or Osteopontin fused to a V5 epitope at the carboxyl terminals, were *in vitro* transcribed and translated in rabbit reticulocyte lysates using the TnT T7 Quick Coupled Transcription/Translation System (Promega) following manufacturer's instructions. The lysate containing translated PHEX protein was mixed with equivalent amounts of lysate containing translated candidate proteins FGF23, FGF23 (R179Q), FRP4, MEPE or Osteopontin and incubated for 30 minutes at 37°. Control reactions were performed by mixing lysates that lacked *in vitro* translated PHEX to the lysates containing candidate proteins. The resulting reactions were subjected to electrophoresis on a 4-20% mini-gels (Bio-Rad), and electroblotted onto PVDF membranes (Millipore). Membranes were probed with 15 ng/ml anti-V5 antibody conjugated to HRP (Invitrogen) and visualized by ECL (Pierce). PHEX enhanced degradation was measured as a reduction in immunoreactive band in PHEX containing lysates relative to control lysates. Results demonstrated FGF 23 and FRP-4 protein levels were decreased in the presence of PHEX. In contrast, levels of full length mutant FGF 23, MEPE (matrix extracellular phosphoglycoprotein) or DMP-1 (dentin matrix protein I) were not affected by the presence of PHEX.

Phosphate Transport Assay. The phosphate transport modulating activity of the FRP 4 and FGF 23 or PHEX proteins are analyzed using methods and techniques known in the art. Specifically, sodium-dependent phosphate uptake is measured in opossum kidney (OK) cells according to the methods described in Cai et al. (1994) *New Engl. J. Med.* 330:1645-1649. Briefly, OK cells are cultured until becoming confluent, harvested and then re-seeded at a density of 1×10^5 cells per 24 well dish. The cells are then re-grown for several days past the time they become confluent and then re-fed with medium containing the 4 proteins as well as medium containing a variety of alternative experimental and control factors. After the incubation period extending from 3 to 48 hours, the medium is removed and the plated cells are re-fed with transport medium containing 32 P-labeled dibasic potassium phosphate and incubated at 37°C for 5 minutes. The cells are then washed, harvested and radioactivity measured via a scintillation counter to monitor uptake of 32 P.

Results of the OK phosphate transport assay performed on conditioned medium containing the FGF-23 protein and control samples showed that conditioned medium that contained the FGF 23 protein induced a statistically significant reduction in phosphate uptake

by the OK cells in comparison with control samples that did not contain this factor (Bowe et al (2001) *Biochemical and Biophysical Research Communication* 284: 977-981, herein incorporated by reference).

5 Results of the OK phosphate transport assay performed on conditioned medium containing the FRP 4 protein and control samples showed that conditioned medium that contained the FRP 4 protein induced a statistically significant reduction in phosphate uptake by the OK cells in comparison with control samples that did not contain this factor.

10 It is to be understood that while the invention has been described in conjunction with the above embodiments, that the foregoing description and examples are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

What is claimed is:

1. A method for modulating the phenotype of a neoplastic cell associated with oncogenic osteomalacia or a cell associated with phosphate homeostasis, comprising delivering an agent that alters the activity of FRP 4 and/or FGF 23 polypeptides or PHEX polypeptide, within the cell.
2. The method of claim 1, wherein the agent is a polynucleotide encoding anti-FRP 4 antibody, a polynucleotide encoding an anti-FGF 23 antibody, a polynucleotide encoding an anti-PHEX antibody, a polynucleotide encoding FGF-23, a polynucleotide encoding FRP 4, a polynucleotide encoding PHEX or a polynucleotide encoding soluble PHEX.
3. The method of claim 1, wherein the agent is a FGF-23 antibody, a FRP-4 antibody, a PHEX antibody, a FGF-23 polypeptide, a FRP-4 polypeptide, a PHEX polypeptide or a soluble PHEX polypeptide.
4. The method of claim 1, wherein the alteration in the activity of FGF-23 or FRP-4 is an inhibition in activity.
5. The method of claim 4, wherein the agent is a polynucleotide encoding anti-FRP 4 antibody, a polynucleotide encoding an anti-FGF 23 antibody, a polynucleotide encoding PHEX or a polynucleotide encoding soluble PHEX.
6. The method of claim 5, wherein the agent delivered to said cell is a polynucleotide encoding PHEX or a polynucleotide encoding soluble PHEX.
7. The method of claim 4, wherein the agent is a FGF-23 antibody, a FRP-4 antibody, a PHEX polypeptide or a soluble PHEX polypeptide.
8. The method of claim 7, wherein the agent is a PHEX polypeptide or a soluble PHEX polypeptide.
9. The method of claim 1, wherein the alteration in the activity of FGF-23 or FRP-4 is an increase in activity.
10. The method of claim 9, wherein the agent is a polynucleotide encoding an anti-PHEX antibody, a polynucleotide encoding FGF-23, a polynucleotide encoding mutant FGF-23 or a polynucleotide encoding FRP 4.
11. The method of claim 9, wherein the agent is a FGF-23 polypeptide, a mutant FGF-23 polypeptide, a FRP-4 polypeptide or PHEX antibody.

12. A method for increasing phosphate re-absorption or increasing serum phosphate in a subject comprising delivering to the subject an effective amount of an agent that inhibits the activity of FRP 4 or FGF 23.
13. The method of claim 12, wherein the agent is a polynucleotide encoding anti-FRP 4 antibody, a polynucleotide encoding an anti-FGF 23 antibody, a polynucleotide encoding FRP 4, an antisense FRP 4 oligonucleotide, an antisense FGF-23 oligonucleotide, a polynucleotide encoding PHEX or a polynucleotide encoding soluble PHEX.
14. The method of claim 12, wherein the agent is a FGF-23 antibody, a FRP-4 antibody, a PHEX polypeptide or a soluble PHEX polypeptide.
15. A method for decreasing phosphate re-absorption or decreasing serum phosphate in a subject comprising delivering to the subject an effective amount of an agent that enhances the activity of FRP 4 or FGF 23 or inhibits the activity of PHEX.
16. The method of claim 15, wherein the agent is a polynucleotide encoding FRP-4, a polynucleotide encoding FGF-23, a polynucleotide encoding mutant FGF-23, a polynucleotide encoding an anti-PHEX antibody, or antisense PHEX oligonucleotide.
17. The method of claim 15, wherein the agent is a FGF-23 polypeptide, a mutant FGF 23 polypeptide, a FRP-4 polypeptide or PHEX antibody.
18. A method of modulating phosphate homeostasis in a subject by delivering to the subject an effective amount of an agent that alters the activity of FRP 4 or FGF 23 within the subject.
19. The method of claim 18, wherein the agent is a polynucleotide encoding PHEX, a polynucleotide encoding soluble PHEX, PHEX protein, soluble PHEX protein, a polynucleotide encoding anti-FRP 4 antibody, a polynucleotide encoding FGF-23 antibody, anti-FGF 23 antibodies, anti-FRP 4 antibody, anti-FGF 23 antibody, an antisense FRP-4 oligonucleotide or an antisense FGF-23 oligonucleotide.
20. A method of inhibiting the activity of FGF 23 and FRP 4 proteins in a subject, comprising delivering to the subject an effective amount of an agent, wherein the agent is soluble PHEX protein, PHEX protein, a polynucleotide encoding soluble PHEX, a polynucleotide encoding PHEX, a polynucleotide encoding anti-FGF 23 and

anti-FRP 4 antibodies and a composition comprising anti-FGF 23 or anti-FRP 4 antibodies.

21. A method of inhibiting the activity of FGF 23 and FRP 4 proteins in a subject comprising delivering to the subject an effective amount of an agent that inhibits transcription and/or translation of FRP 4 and FGF 23 genes in the subject.
22. A method of enhancing the biological activity of FGF 23 and FRP 4 proteins in a subject, comprising delivering to the subject an effective amount of an agent, wherein the agent is an anti-PHEX antibody, a polynucleotide encoding an anti-PHEX antibody, a polynucleotide encoding FGF 23 and FRP 4 proteins and a composition comprising an effective amount of FGF 23 or FRP 4 proteins.
23. A method of enhancing the biological activity of FGF 23 and FRP 4 proteins in a subject comprising delivering to the subject an effective amount of an agent that inhibits transcription and/or translation of PHEX genes in the subject.
24. A method for modulating renal phosphate transport in a subject, comprising delivering to the subject an effective amount of an agent that alters the activity of FRP 4 and FGF 23 or PHEX, in the subject.
25. A method of modulating renal phosphate transport, comprising delivering to the subject an effective amount of an agent that alters the expression of FRP 4 and FGF 23 polynucleotides or PHEX polynucleotide.
26. A method of alleviating an oncogenic osteomalacia-associated symptom, comprising altering the expression of FRP 4 and FGF 23 polynucleotides or PHEX polynucleotide, within an OOM-associated neoplastic cell.
27. The method of claim 26, wherein the symptom is hypophosphatemia, phosphaturia, low serum concentrations of 1,25-dihydroxyvitamin D, or osteomalacia.
28. A method for treating a phosphate homeostasis-related disease, comprising delivering to the subject an agent that alters the activity of FRP 4 and FGF 23 polynucleotides or PHEX polynucleotide.
29. The method of claim 28, wherein the disease is X-linked hypophosphatemia rickets, oncogenic osteomalacia, rhabdomyolysis, cardiomyopathy, tumoral calcinosis, renal failure or bone mineralization.

30. A method for detecting a neoplastic cell associated with oncogenic osteomalacia, comprising contacting a suitable sample derived from a cell with one or more suitable polynucleotide probes, wherein the one or more suitable polynucleotide probes are FRP 4 or FGF 23 under conditions of moderate hybridization stringency and detecting any hybridized, complementary polynucleotides, thereby detecting the oncogenic osteomalacia-associated neoplastic cell.
- 5
31. A method for detecting a neoplastic cell associated with oncogenic osteomalacia, comprising contacting a suitable sample derived from a cell with one or more primer pair selective for a polynucleotide encoding one or more proteins, wherein the one or more proteins are FRP 4 or FGF 23, performing a polymerase chain reaction, and detecting any amplified polynucleotides, thereby detecting the oncogenic osteomalacia-associated neoplastic cell.
- 10
32. A method of screening for candidate therapeutic agents that modulate the expression of a gene, wherein the gene is FRP 4 in combination with FGF 23 and PHEX, the method comprising contacting a target cell with a test agent and monitoring expression of one or more of said genes, wherein a test agent which modifies the expression of one or more of said gene is a candidate therapeutic agent.
- 15
33. The method of claim 32, wherein the candidate agent is a biological or chemical compound, wherein the biological or chemical compound is a polypeptide, a polynucleotide, a ribozyme, or a small organic molecule.
- 20
34. A method of screening for candidate agents capable of altering the biological activity of one or more polypeptides encoded by the a gene, wherein the polypeptides are FRP 4 in combination with FGF 23 and PHEX, the method comprising comprising contacting a target cell expressing said polypeptide with a test agent and monitoring activity of the expressed polypeptide product, wherein a test agent which modifies the activity of said polypeptide is a candidate agent.
- 25
35. The method of claim 34, wherein the candidate agent is a biological or chemical compound, wherein the biological or chemical compound is a polypeptide, a polynucleotide, a ribozyme, or a small organic molecule.
- 30
36. The method of claim 34, wherein the candidate agent inhibits the protein stability of FRP-4 or FGF-23.

GZ206543SL

SEQUENCE LISTING

<110> Genzyme Corporation;Schiavi,Susan;Finnegan, Richard

<120> COMPOSITIONS AND METHODS TO REGULATE
SERUM PHOSPHATE

<130> GZ 2065.43

<140> Not Yet Assigned

<141> 2002-05-10

<150> US 60/296,298

<151> 2001-06-06

<150> US 60/290,483

<151> 2001-05-11

<160> 14

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2840

<212> DNA

<213> Homo sapiens

<400> 1

cagcggccgc	tgaattctag	ggcgggttcg	cgccccgaag	gctgagagct	ggcgtgctc	60
gtgccctgtg	tgccagacgg	cggagctccg	cggccggacc	ccgcggcccc	gctttgctgc	120
cgactggagt	ttgggggaag	aaactctcct	gcgccccaga	agatttcttc	ctcggcgaag	180
ggacagcgaa	agatgagggg	ggcaggaaga	gaaggcgctt	tctgtctgcc	ggggtcgag	240
cgcgagaggg	cagtgccatg	ttcctctcca	tcctagtggc	gctgtgacct	tggtgcacc	300
tgccgttggg	cgtgcgcggc	gcgccctgcg	aggcgggtgcg	catccctatg	tgccggcaca	360
tgccctggaa	catcacgcgg	atgccccacc	acctgcacca	cagcacgcag	gagaacgcc	420
tccttgccat	cgagcagtac	gaggagctgg	tggacgtgaa	ctgcagcgcc	gtgctgcgt	480
tcttcttctg	tgccatgtac	gcgcccat	gcacctgga	gttcttgac	gacctatca	540
agccgtgcaa	gtcgggtg	caacgcgcgc	gcgacgactg	cgagccccct	atgaagatgt	600
acaaccacag	ctggcccga	agcctggcct	gcgacgagct	gcctgtctat	gaccgtggcg	660
tgtgcat	gcctgaagcc	atcgctacgg	acctcccga	ggatgttaag	tggtatagaca	720
tcacaccaga	catgatggta	caggaaaggc	ctcttgatgt	tgactgtaaa	cgccaaagcc	780
ccgatcgggtg	caagtgtaaa	aagggtgaagc	caactttggc	aacgtatctc	agcaaaaact	840
acagctatgt	tattcatgcc	aaaataaaaag	ctgtgcagag	gagtggctgc	aatgaggtca	900
caacggtggg	ggatgtaaaa	gagatcttca	agtcctcatc	acccatccct	cgaactcaag	960
tcccgtcat	tacaaattct	tcttgccagt	gtccacacat	cctgccccat	caagatgttc	1020
tcatcatgtg	ttacgagtgg	cgttcaagga	tgatgcttct	tgaaaattgc	ttagttgaaa	1080
aatggagaga	tcagcttagt	aaaagatcca	tacagtggga	agagaggctg	caggaacagc	1140
ggagaacagt	tcaggacaag	aagaaaacag	ccgggcgcac	cagtcgtagt	aatcccccca	1200
aaccaaaggg	aaagcctcct	gtcccaaac	cagccagtcc	caagaagaac	attaaaacta	1260
ggagtgc	gaagagaaca	aaccggaaaa	gagtgtgagc	taactagttt	ccaaagcgga	1320
gacttccgac	ttccttacag	gatgaggctg	ggcattgcct	gggacagcct	atgtaaggcc	1380
atgtgcccct	tgccctaaca	actcactgca	gtgctcttca	tagacacatc	ttgcagcatt	1440
tttcttaagg	ctatgcttca	gtttttcttt	gtaagccatc	acaagccata	gtggtaggtt	1500
tgcccttttg	tacagaagg	gagttaaagc	tggtggaaaa	ggcttattgc	attgcattca	1560
gagtaacctg	tgtgcatact	ctagaagagt	agggaaaata	atgcttggtt	caattcgacc	1620
taatatgtgc	attgtaaaat	aaatgccata	tttcaaacaa	aacacgtaat	ttttttacag	1680
tatgttttat	taccttttga	tatctgttgt	tgcaatgtta	gtgatgtttt	aaaatgtgat	1740
gaaaatataa	tgtttttaag	aaggaacagt	agtggaatga	atgttaaaaag	atctttatgt	1800
gtttatgggc	tgcagaagga	tttttgtgat	gaaaggggat	tttttgaaaa	attagagaag	1860
tagcatatgg	aaaattataa	tgtgtttttt	taccaatgac	ttcagtttct	gttttttagct	1920
agaaacttaa	aaacaaaaat	aataataaag	aaaaataaat	aaaaaggaga	ggcagacaat	1980

GZ206543SL

```

gtctggattc ctgttttttg gttacctgat ttccatgac atgatgcttc ttgtcaacac 2040
cctcttaagc agcaccagaa acagtgaagt tgtctgtacc attaggagtt aggtactaat 2100
tagttggcta atgctcaagt atttataacc cacaagagag gtatgtcact catcttactt 2160
cccaggacat ccaccctgag aataatttga caagcttaaa aatggccttc atgtgagtgc 2220
caaattttgt tttctttcat ttaaattttt tctttgccta aatacatgtg agaggagtta 2280
aatataaatg tacagagagg aaagttagt tccacctctg aaatgagaat tacttgacag 2340
ttgggatact ttaatcagaa aaaaagaact tatttgcagc attttatcaa caaatttcat 2400
aattgtggac aattggaggc atttatttta aaaaacaatt ttattggcct tttgctaaca 2460
cagtaagcat gtattttata aggcattcaa taaatgcaca acgcccacaa gaaataaaat 2520
cctactaat cctactctcc actacacaga ggtaatcact attagtattt tggcatatta 2580
ttctccaggt gtttgcttat gcacttataa aatgatttga acaaataaaa ctaggaaacct 2640
gtatacatgt gtttcataac ctgcctcctt tgcttggccc tttattgaga taagttttcc 2700
tgtcaagaaa gcagaaacca tctcatttct aacagctgtg ttatattcca tagtatgcat 2760
tactcaacaa actgtttgtc tattggatac ttagggtggt tcttactga caatactgaa 2820
taaacatctc accggaattc

```

<210> 2

<211> 346

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Phe Leu Ser Ile Leu Val Ala Leu Cys Leu Trp Leu His Leu Ala
1      5      10      15
Leu Gly Val Arg Gly Ala Pro Cys Glu Ala Val Arg Ile Pro Met Cys
20     25     30
Arg His Met Pro Trp Asn Ile Thr Arg Met Pro Asn His Leu His His
35     40     45
Ser Thr Gln Glu Asn Ala Ile Leu Ala Ile Glu Gln Tyr Glu Glu Leu
50     55     60
Val Asp Val Asn Cys Ser Ala Val Leu Arg Phe Phe Phe Cys Ala Met
65     70     75     80
Tyr Ala Pro Ile Cys Thr Leu Glu Phe Leu His Asp Pro Ile Lys Pro
85     90     95
Cys Lys Ser Val Cys Gln Arg Ala Arg Asp Asp Cys Glu Pro Leu Met
100    105    110
Lys Met Tyr Asn His Ser Trp Pro Glu Ser Leu Ala Cys Asp Glu Leu
115    120    125
Pro Val Tyr Asp Arg Gly Val Cys Ile Ser Pro Glu Ala Ile Val Thr
130    135    140
Asp Leu Pro Glu Asp Val Lys Trp Ile Asp Ile Thr Pro Asp Met Met
145    150    155    160
Val Gln Glu Arg Pro Leu Asp Val Asp Cys Lys Arg Leu Ser Pro Asp
165    170    175
Arg Cys Lys Cys Lys Lys Val Lys Pro Thr Leu Ala Thr Tyr Leu Ser
180    185    190
Lys Asn Tyr Ser Tyr Val Ile His Ala Lys Ile Lys Ala Val Gln Arg
195    200    205
Ser Gly Cys Asn Glu Val Thr Thr Val Val Asp Val Lys Glu Ile Phe
210    215    220
Lys Ser Ser Ser Pro Ile Pro Arg Thr Gln Val Pro Leu Ile Thr Asn
225    230    235    240
Ser Ser Cys Gln Cys Pro His Ile Leu Pro His Gln Asp Val Leu Ile
245    250    255
Met Cys Tyr Glu Trp Arg Ser Arg Met Met Leu Leu Glu Asn Cys Leu
260    265    270
Val Glu Lys Trp Arg Asp Gln Leu Ser Lys Arg Ser Ile Gln Trp Glu
275    280    285
Glu Arg Leu Gln Glu Gln Arg Arg Thr Val Gln Asp Lys Lys Lys Thr
290    295    300
Ala Gly Arg Thr Ser Arg Ser Asn Pro Pro Lys Pro Lys Gly Lys Pro
305    310    315    320
Pro Ala Pro Lys Pro Ala Ser Pro Lys Lys Asn Ile Lys Thr Arg Ser

```

GZ206543SL

Ala Gln Lys Arg Thr Asn Pro Lys Arg Val
 340 330 345

335

<210> 3
 <211> 1612
 <212> DNA
 <213> Homo sapiens

<400> 3
 cggcaaaaag gaggggaatcc agtctaggat cctcacacca gctacttgca agggagaagg 60
 aaaaaggccag taaggcctgg gccaggagag tcccgcacagg agtggtcagg ttcaatctca 120
 gcaccagcca ctacagagcag ggcacgatgt tggggggccc cctcaggctc tgggtctgtg 180
 ccttggtgcag cgtctgcagc atgagcgctc tcagagccta tcccaatgcc tcccactgc 240
 tcgggtccag ctgggggtggc ctgatccacc tgtacacagc cacagccagg aacagctacc 300
 acctgcagat ccacaagaat ggccatgtgg atggcgacc ccacagacc atctacagt 360
 ccttgatgat cagatcagag gatgctggct ttgtggtgat tacagggtgt atgagcagaa 420
 gatacctctg catggatttc agaggcaaca tttttggatc acactatttc gaccgggaga 480
 actgcagggt ccaacaccag acgctggaaa acgggtacga cgtctaccac tctctcagt 540
 atcacttcct ggctcagtct ggccgggcca agagagcctt cctgccaggc atgaaccac 600
 ccccgactc ccagttcctg tcccggagga acgagatccc cctaattcac ttcaacaccc 660
 ccataccacg gcggcacacc cggagcgccg aggacgactc ggagcgggac cccctgaacg 720
 tgctgaagcc ccggggcccg atgaccccg cccggcctc ctgttcacag gagctcccga 780
 gcgccgagga caacagcccg atggccagtg acccattagg ggtggtcagg ggcggtcgag 840
 tgaacacgca cgctggggga acggggcccg aaggctgccg ccccttcgcc aagttcatct 900
 agggctcgtg gaagggcacc ctctttaacc catccctcag caaacgcagc tcttccaag 960
 gaccaggctc cttagcgttc cgaggatggg aaaggtgaca ggggcatgta tggaaattgc 1020
 tgcttctctg ggttcccttc cacaggaggt cctgtgagaa ccaaccttg aggcccaagt 1080
 catgggggtt caccgccttc ctactccat atagaacacc tttcccaata ggaaacccca 1140
 acaggtaaac tagaaatttc ccttcatga aggtagagag aagggtctc tcccaacata 1200
 tttctcttc ttgtgcctct cctctttatc acttttaagc ataaaaaaa aaaaaaaa 1260
 aaaaaaaaaa aaaagcagtg ggttcctgag ctcaagactt tgaagggtgta gggaagagga 1320
 aatcggagat ccagaaagct tctccactgc cctatgcatt tatgttagat gcccgatcc 1380
 cactggcatt tgagtgtgca aaccttgaca ttaacagctg aatggggcaa gttgatgaaa 1440
 acactacttt caagccttcg ttcttcttg agcatctctg gggaagagct gtcaaaagac 1500
 tgggtgtagg ctgggtgaaa cttgacagct agacttgatg cttgctgaaa tgaggcagga 1560
 atcataatag aaaactcagc ctccctacag ggtgagcacc ttctgtctcg ct 1612

<210> 4
 <211> 251
 <212> PRT
 <213> Homo sapiens

<400> 4
 Met Leu Gly Ala Arg Leu Arg Leu Trp Val Cys Ala Leu Cys Ser Val
 1 5 10 15
 Cys Ser Met Ser Val Leu Arg Ala Tyr Pro Asn Ala Ser Pro Leu Leu
 20 25 30
 Gly Ser Ser Trp Gly Gly Leu Ile His Leu Tyr Thr Ala Thr Ala Arg
 35 40 45
 Asn Ser Tyr His Leu Gln Ile His Lys Asn Gly His Val Asp Gly Ala
 50 55 60
 Pro His Gln Thr Ile Tyr Ser Ala Leu Met Ile Arg Ser Glu Asp Ala
 65 70 75 80
 Gly Phe Val Val Ile Thr Gly Val Met Ser Arg Arg Tyr Leu Cys Met
 85 90 95
 Asp Phe Arg Gly Asn Ile Phe Gly Ser His Tyr Phe Asp Pro Glu Asn
 100 105 110
 Cys Arg Phe Gln His Gln Thr Leu Glu Asn Gly Tyr Asp Val Tyr His
 115 120 125
 Ser Pro Gln Tyr His Phe Leu Val Ser Leu Gly Arg Ala Lys Arg Ala
 130 135 140

GZ206543SL

Phe Leu Pro Gly Met Asn Pro Pro Pro Tyr Ser Gln Phe Leu Ser Arg
 145 150 155 160
 Arg Asn Glu Ile Pro Leu Ile His Phe Asn Thr Pro Ile Pro Arg Arg
 165 170 175
 His Thr Arg Ser Ala Glu Asp Asp Ser Glu Arg Asp Pro Leu Asn Val
 180 185 190
 Leu Lys Pro Arg Ala Arg Met Thr Pro Ala Pro Ala Ser Cys Ser Gln
 195 200 205
 Glu Leu Pro Ser Ala Glu Asp Asn Ser Pro Met Ala Ser Asp Pro Leu
 210 215 220
 Gly Val Val Arg Gly Gly Arg Val Asn Thr His Ala Gly Gly Thr Gly
 225 230 235 240
 Pro Glu Gly Cys Arg Pro Phe Ala Lys Phe Ile
 245 250

<210> 5

<211> 2584

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> 2230, 2231, 2232, 2233

<223> n = A,T,C or G

<400> 5

aacgcctcgc tcttgagacc agccacaaa ccacgaaaag tgactttctt ctcgtgtgct 60
 ctctacggcc ctctgatgg aagcagaaac agggagcagc gtggagactg gaaagaaggc 120
 caacagaggc actcgaattg ccctggcgt gttgtcggg ggaccctag ttctgggcac 180
 gatccctctt ctaggagtca aggtctctta agtctccaag ctaaacagga gtactgcctg 240
 aagccagaat gcatcgaagc ggctgctgcc atcttaagta aagtaaatct gtctgtggat 300
 ccttggtgata atttcttccg gttcgtctgt gatggctgga taagcaataa tccaattccc 360
 gaagatatgc caagctatgg ggtttatcct tggctgagac ataattgtga cctcaagttg 420
 aaggaacttt tggagaaatc aatcagtaga aggcgggaca ccgaagccat acagaaagcc 480
 aaaatccttt attcatcctg catgaatgag aaagcgattg aaaaagcaga tgccaagcca 540
 ctgctacaca tcttacggca ttcaccttc cgctggcccg tgcttgaatc taatatggc 600
 cctgaagggg ttgggtcaga gagaaagtgc agccttctgc agacacttgc aacgtttcgt 660
 ggtcaataca gcaattctgt gttcatccgt ttgtatgtgt cccctgatga caaagcatcc 720
 aatgaacata tcttgaagct ggaccaagca acactctccc tggccgtgag ggaagactac 780
 cttgataaca gtacagaagc caagtcttat cgggatgccc tttaacagtt catgggtggat 840
 actgccgtgc ttttaggagc taacagtccc agagcagagc atgacatgaa gtcagtgtc 900
 agattggaaa ttaagatagc tgagataatg attccacatg aaaaccgaac cagcagggcc 960
 atgtacaaca aaatgaacat ttctgaactg agtgctatga ttccccagtt cgactggctg 1020
 ggctacatca agaaggctcat tgacaccaga ctctaccccc atctgaaaga catcagcccc 1080
 tccgagaaag tgggtggccc cgtcccgcag tactttaaag atttgtttag gatattaggg 1140
 tctgagagaa agaagaccat tgccaaactat ttggtgtgga gaattggtta ttccagaatt 1200
 ccaaacccta gcaggcgctt tcagtataga tggctggaat tctcaagggt aatccagggg 1260
 accacaactt tgcgcctca atgggacaaa tgtgtaaact ttattgaaag tgccctccct 1320
 tatgttgttg gaaagatggt tgtagatgtg tacttcagg aagataagaa ggaaatgatg 1380
 gaggaattgg ttgagggcgt tcgctgggccc tttattgaca tgctagagaa agaaaatgag 1440
 tggatggatg caggaacgaa aaggaaaagg aaagaaaagg cgagagctgt tttggcaaaa 1500
 gttggctatc cagagtttat aatgaatgat actcatgtta atgaagacct caaagctatc 1560
 aagttttcag aagccgacta ctttggcaac gtcctacaaa ctgcgaagta tttagcacag 1620
 tctgatttct tctggctaag aaaagccgtt ccaaaaacag atggtttaca aatccgacga 1680
 ctgtcaatgc cttctacagt gcatccacca accagatccg atttccagca ggagagctcc 1740
 agaagccttt cttttgggga acagaatatc ctcgatctct gagttatggt gctataggag 1800
 taattgtcgg acatgaattt acacatggat ttgataataa tggtagaaaa tatgataaaa 1860
 atggaaacct ggaatccttg tggctacttg aatcagaaga aaagttaag gaaaaacaa 1920
 aatgcatgat taaccagtat agcaactatt attggaagaa agctggctta aatgtcaagg 1980
 ggaagaggac cctggggagaa aatattgctg ataattggag cctgcgggaa gcttttaggg 2040
 cttacaggaa atggataaat gacagaaggc agggacttga ggagcctctt ctaccaggca 2100
 tcacattcac caacaaccag ctcttcttcc tgagttatgc tcatgtgagg tgcaattcct 2160

GZ206543SL

```

acagaccaga agctgccgga gaacaagtcc aaattggtgc tcacagtccc cctcagttta 2220
ggtaaatggn nnttagtaa ctttgaagaa ttccagaaaag cttttaactg tccaccaaat 2280
tccacgatga acagaggcat ggactcctgc cgactctggt agctgggacg ctggtttatg 2340
gcaccttgag acagttgcac agtgccagcg gaggctgcac tgagccttca tcgcccattg 2400
ctttaggcct ggagactttc atttttagtg cattttcatt atttgggtag gtgacctgct 2460
tggatctaga cagcatctgt tcaaagtgtt agggcttata aagtggataa taagaatgaa 2520
ctaagtatgt ttctttagaa aatcaaacca acaaaaataa atccctaggc tacttttgtt 2580
aaaa

```

<210> 6

<211> 471

<212> PRT

<213> Homo sapiens

<400> 6

```

Met Pro Ser Tyr Gly Val Tyr Pro Trp Leu Arg His Asn Val Asp Leu
1      5      10      15
Lys Leu Lys Glu Leu Leu Glu Lys Ser Ile Ser Arg Arg Arg Asp Thr
20      25      30
Glu Ala Ile Gln Lys Ala Lys Ile Leu Tyr Ser Ser Cys Met Asn Glu
35      40      45
Lys Ala Ile Glu Lys Ala Asp Ala Lys Pro Leu Leu His Ile Leu Arg
50      55      60
His Ser Pro Phe Arg Trp Pro Val Leu Glu Ser Asn Ile Gly Pro Glu
65      70      75      80
Gly Val Trp Ser Glu Arg Lys Phe Ser Leu Leu Gln Thr Leu Ala Thr
85      90      95
Phe Arg Gly Gln Tyr Ser Asn Ser Val Phe Ile Arg Leu Tyr Val Ser
100     105     110
Pro Asp Asp Lys Ala Ser Asn Glu His Ile Leu Lys Leu Asp Gln Ala
115     120     125
Thr Leu Ser Leu Ala Val Arg Glu Asp Tyr Leu Asp Asn Ser Thr Glu
130     135     140
Ala Lys Ser Tyr Arg Asp Ala Leu Tyr Lys Phe Met Val Asp Thr Ala
145     150     155     160
Val Leu Leu Gly Ala Asn Ser Ser Arg Ala Glu His Asp Met Lys Ser
165     170     175
Val Leu Arg Leu Glu Ile Lys Ile Ala Glu Ile Met Ile Pro His Glu
180     185     190
Asn Arg Thr Ser Glu Ala Met Tyr Asn Lys Met Asn Ile Ser Glu Leu
195     200     205
Ser Ala Met Ile Pro Gln Phe Asp Trp Leu Gly Tyr Ile Lys Lys Val
210     215     220
Ile Asp Thr Arg Leu Tyr Pro His Leu Lys Asp Ile Ser Pro Ser Glu
225     230     235     240
Asn Val Val Val Arg Val Pro Gln Tyr Phe Lys Asp Leu Phe Arg Ile
245     250     255
Leu Gly Ser Glu Arg Lys Lys Thr Ile Ala Asn Tyr Leu Val Trp Arg
260     265     270
Met Val Tyr Ser Arg Ile Pro Asn Leu Ser Arg Arg Phe Gln Tyr Arg
275     280     285
Trp Leu Glu Phe Ser Arg Val Ile Gln Gly Thr Thr Leu Leu Pro
290     295     300
Gln Trp Asp Lys Cys Val Asn Phe Ile Glu Ser Ala Leu Pro Tyr Val
305     310     315     320
Val Gly Lys Met Phe Val Asp Val Tyr Phe Gln Glu Asp Lys Lys Glu
325     330     335
Met Met Glu Glu Leu Val Glu Gly Val Arg Trp Ala Phe Ile Asp Met
340     345     350
Leu Glu Lys Glu Asn Glu Trp Met Asp Ala Gly Thr Lys Arg Lys Ala
355     360     365
Lys Glu Lys Ala Arg Ala Val Leu Ala Lys Val Gly Tyr Pro Glu Phe
370     375     380

```

GZ206543SL

Ile	Met	Asn	Asp	Thr	His	Val	Asn	Glu	Asp	Leu	Lys	Ala	Ile	Lys	Phe
385					390					395					400
Ser	Glu	Ala	Asp	Tyr	Phe	Gly	Asn	Val	Leu	Gln	Thr	Arg	Lys	Tyr	Leu
			405						410					415	
Ala	Gln	Ser	Asp	Phe	Phe	Trp	Leu	Arg	Lys	Ala	Val	Pro	Lys	Thr	Asp
			420					425					430		
Gly	Leu	Gln	Ile	Arg	Arg	Leu	Ser	Met	Pro	Ser	Thr	Val	His	Pro	Pro
		435					440					445			
Thr	Arg	Ser	Asp	Phe	Gln	Gln	Glu	Ser	Ser	Arg	Ser	Leu	Ser	Phe	Gly
	450					455					460				
Glu	Gln	Asn	Ile	Leu	Asp	Leu									
465					470										

<210> 7
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 7
 gagaaggcaa ccaaagtgc a 21

<210> 8
 <211> 24
 <212> DNA
 <213> Homo sapiens

<400> 8
 gaagcactgg atccacttgc ggcg 24

<210> 9
 <211> 19
 <212> DNA
 <213> Homo sapiens

<400> 9
 gtatgccaca agggaaagg 19

<210> 10
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 10
 ttctattaaa ggctataatg 20

<210> 11
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 11
 ccaatgactt cagtttctgt t 21

<210> 12
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 12
 taagcttgct aaattattct cag 23

<210> 13

GZ206543SL

<211> 22
<212> DNA
<213> Homo sapiens

<400> 13
attgagtgga tggatgcagg aa

22

<210> 14
<211> 20
<212> DNA
<213> Homo sapiens

<400> 14
aggaaaaggct tctggagctc

20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/18609

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 39/395, 38/00; A01N 43/04

US CL : 424/139.1; 514/2, 44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/139.1; 514/2, 44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	WO 00/50580 A2 (UNIVERSITE DE MONTREAL) 31 August 2000 (31.08.2000), see pages 4-6, 8, 9, and 31-33.	1-20, 22-29 ----- 1-36
Y	THE ADHR CONSORTIUM. Autosomal Dominant Hypophosphatemic Rickets is Associated with Mutations in FGF23. Nature Genetics, November 2000, Vol. 26, pages 345-348, especially pages 345 and 347.	1-36
Y, P	JOHN et al. A Case of Neuroendocrine Oncogenic Osteomalacia Associated with PHEX and Fibroblast Growth Factor-23 Expressing Sinusoidal Malignant Schwannoma. Bone, October 2001, Vol. 29, No. 4, pages 393-402, especially pages 393, 394, 397, 398, and 401.	1-36

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier application or patent published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

&

document member of the same patent family

Date of the actual completion of the international search

10 September 2002 (10.09.2002)

Date of mailing of the international search report

02 OCT 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Felicia D. Roberts for
Jaket Andres

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

PCT/US02/18609

Continuation of B. FIELDS SEARCHED Item 3:

STN, EAST

search terms: FRP-4, frizzled, frezzled, FGF-23, PHEX, osteomalacia

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.